{"36440b4c5f784d80586c97494e074aaa8a636fc2": [["IntroductionWhile it is clear that mortality from SARS-CoV-2 infection (COVID-19) increases with age [1] [2] [3] , the association between frailty and mortality is not well understood [4, 5] .", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 61, 70], ["frailty", "DISEASE", 139, 146], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["2 infection", "PROBLEM", 59, 70], ["COVID", "TEST", 72, 77]]], ["This relationship has clinical implications as the National Institute for Health and Care Excellence (NICE) guidelines in England and Wales recommend the integration of a frailty assessment into algorithms used to guide decisions including admission to critical care [6] .", [["a frailty assessment", "TEST", 169, 189]]], ["Furthermore, other demographic factors relevant to mortality such as ethnicity or socioeconomic position have yet to be comprehensively described in relation to COVID-19 [7, 8] .IntroductionOur aim was to investigate the relationship between frailty, ethnicity, socioeconomic position and mortality in a cohort of older patients presenting to hospital with COVID-19, in order to: (1) quantify the mortality from COVID-19; (2) identify any interactions with frailty and other demographic factors in this population.ParticipantsPatients admitted to an urban teaching hospital aged \u2265 70 were included if they tested positive for SARS-CoV-2 by combined throat and high-nasal swab on reverse-transcriptase polymerase chain reaction or if there was high clinical suspicion (on the basis of clinical, imaging and laboratory results, as determined by specialist infectious diseases physicians) for COVID-19 up until 23rd April 2020.", [["throat", "ANATOMY", 649, 655], ["frailty", "DISEASE", 242, 249], ["frailty", "DISEASE", 457, 464], ["SARS", "DISEASE", 626, 630], ["infectious diseases", "DISEASE", 854, 873], ["patients", "ORGANISM", 320, 328], ["Patients", "ORGANISM", 526, 534], ["CoV-2", "ORGANISM", 631, 636], ["throat", "ORGANISM_SUBDIVISION", 649, 655], ["reverse-transcriptase", "PROTEIN", 679, 700], ["patients", "SPECIES", 320, 328], ["Participants", "SPECIES", 514, 526], ["Patients", "SPECIES", 526, 534], ["SARS-CoV", "SPECIES", 626, 634], ["COVID", "TEST", 161, 166], ["COVID", "TREATMENT", 357, 362], ["COVID", "TEST", 412, 417], ["SARS", "PROBLEM", 626, 630], ["CoV", "TEST", 631, 634], ["combined throat", "PROBLEM", 640, 655], ["high-nasal swab", "PROBLEM", 660, 675], ["reverse-transcriptase polymerase chain reaction", "PROBLEM", 679, 726], ["imaging", "TEST", 794, 801], ["COVID", "TEST", 890, 895], ["throat", "ANATOMY", 649, 655], ["nasal", "ANATOMY", 665, 670]]], ["During the pandemic, the index of suspicion for SARS-CoV-2 infection was very high, so each older person needing hospitalisation was systematically assessed for COVID-19.", [["SARS", "DISEASE", 48, 52], ["infection", "DISEASE", 59, 68], ["SARS-CoV-2", "ORGANISM", 48, 58], ["person", "SPECIES", 98, 104], ["SARS-CoV-2", "SPECIES", 48, 58], ["the index", "TEST", 21, 30], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["2 infection", "PROBLEM", 57, 68], ["COVID", "TEST", 161, 166]]], ["Therefore, the control group comprised patients aged \u2265 70 who had been admitted within the same time period who reliably did not have COVID-19.OutcomeOur primary outcome was all-cause mortality determined up until 13th May 2020.", [["COVID-19", "CHEMICAL", 134, 142], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["COVID", "TEST", 134, 139]]], ["Deaths occurring outside of hospital were captured through daily updates on the NHS Spine, a collection of local and national databases and systems containing demographic information.ExposuresFrailty was quantified by the Clinical Frailty Scale (CFS) score [9] capturing patients' clinical state 2 weeks prior to admission.", [["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["Spine", "ANATOMY", 84, 89]]], ["Socioeconomic position was estimated through the Index of Multiple Deprivation (IMD) (along with Health, Income, Education sub-indices) which is an ecological measure determined by home postcodes [10] .", [["Socioeconomic position", "TREATMENT", 0, 22]]], ["Ethnicity was self-reported in hospital administrative data.Ethics approvalsThese analyses were conducted as part of a service evaluation project and individual consent was not necessary as determined by the NHS Health Research Authority (HRA), the regulatory body for medical research for England, UK.", [["body", "ORGANISM_SUBDIVISION", 260, 264], ["These analyses", "TEST", 76, 90], ["a service evaluation", "TEST", 117, 137]]], ["The HRA has the Research Ethics Service as one of its core functions and they determined the project was exempt from the need to obtain approval from an NHS Research Ethics Committee [11] .Statistical analysisDifferences in continuous or categorical variables were assessed using t tests and \u03c7 2 tests, respectively.", [["Statistical analysisDifferences in continuous or categorical variables", "PROBLEM", 189, 259], ["t tests and \u03c7 2 tests", "TEST", 280, 301]]], ["Cox proportional hazards models estimated differences in survival between COVID-19 cases and non-COVID-19 controls.", [["Cox proportional hazards", "PROBLEM", 0, 24], ["COVID", "TEST", 74, 79], ["non-COVID", "TEST", 93, 102], ["differences", "OBSERVATION_MODIFIER", 42, 53]]], ["Frailty was considered a continuous variable, ethnicity was classified into South Asian, Black, White, Mixed, Other, and deciles of IMD (1 = most advantaged; 10 = most disadvantaged) and its sub-indices were used in univariable and multivariable models.", [["Frailty", "DISEASE", 0, 7], ["IMD", "DISEASE", 132, 135], ["its sub-indices", "TEST", 187, 202]]], ["Interactions between Clinical Frailty Score and COVID-19 status were assessed.", [["Clinical Frailty Score", "TEST", 21, 43], ["COVID", "TEST", 48, 53]]], ["Post-estimation procedures included Schoenfeld residuals to test heteroskedasticity.", [["Post-estimation procedures", "TREATMENT", 0, 26], ["Schoenfeld residuals to test heteroskedasticity", "PROBLEM", 36, 83]]], ["Stata 14.1 (StataCorp, Texas, USA) was used for all analyses.ResultsA total of 217 COVID-19 cases and 160 non-COVID-19 controls were identified.", [["controls", "ORGANISM", 119, 127], ["Stata", "TEST", 0, 5], ["all analyses", "TEST", 48, 60], ["ResultsA", "TEST", 61, 69], ["COVID", "TEST", 83, 88], ["cases", "TEST", 92, 97], ["non-COVID", "TEST", 106, 115]]], ["In COVID-19 cases, the mean age was 80.0 (SD 6.8) (range 70-99) years ( Table 1 ).", [["the mean age", "TEST", 19, 31], ["SD", "TEST", 42, 44]]], ["The majority of cases were men (n = 134, 62%) or of white ethnicity (n = 138, 63%).", [["men", "ORGANISM", 27, 30], ["men", "SPECIES", 27, 30], ["white ethnicity", "TEST", 52, 67]]], ["There was a normal distribution of clinical frailty scores and the median Index of Multiple Deprivation decile was 4 (IQR 3, 6).", [["clinical frailty scores", "PROBLEM", 35, 58], ["normal", "OBSERVATION_MODIFIER", 12, 18], ["distribution", "OBSERVATION_MODIFIER", 19, 31], ["Multiple", "OBSERVATION_MODIFIER", 83, 91], ["Deprivation", "OBSERVATION", 92, 103]]], ["There were no significant differences in age, ethnicity, Index of Multiple Deprivation decile, or Clinical Frailty Scale score between cases and controls ( Table 1 ).", [["Multiple Deprivation decile", "PROBLEM", 66, 93], ["Clinical Frailty Scale score", "TEST", 98, 126], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Median length of stay was 9 (IQR 4, 7) and 4 (IQR 2, 8) in COVID-19 and controls, respectively (p < 0.01).ResultsIn univariable models, COVID-19, older age and South Asian ethnicity were associated with higher mortality, though no measure of socioeconomic position demonstrated any association (Table 2) .", [["IQR", "TEST", 29, 32], ["IQR", "TEST", 46, 49], ["COVID", "TEST", 59, 64], ["COVID", "TEST", 136, 141]]], ["For frailty, differences in effect size were evident between cases (HR 1.02, 95% CI 0.93-1.12, p = 0.71) and controls (HR 1.99, 95% CI 1.46-2.72, p < 0.01).", [["frailty", "PROBLEM", 4, 11], ["HR", "TEST", 68, 70], ["CI", "TEST", 81, 83], ["p", "TEST", 95, 96], ["controls", "TEST", 109, 117], ["HR", "TEST", 119, 121], ["CI", "TEST", 132, 134], ["p", "TEST", 146, 147], ["size", "OBSERVATION_MODIFIER", 35, 39]]], ["In the multivariable model, these relationships remained consistent: age (HR 1.04, 95% CI 1.01-1.07, p < 0.01), South Asian ethnicity (HR 1.13, 95% CI 1.13-3.51, p = 0.02) ( Table 2) .ResultsThe different associations with frailty according to COVID-19 status was confirmed by demonstrating an interaction term (HR 0.51, 95% CI 0.37-0.71, p < 0.01).", [["frailty", "DISEASE", 223, 230], ["COVID", "PROTEIN", 244, 249], ["HR", "TEST", 74, 76], ["CI", "TEST", 87, 89], ["p", "TEST", 101, 102], ["HR", "TEST", 135, 137], ["CI", "TEST", 148, 150], ["p", "TEST", 162, 163], ["COVID", "TEST", 244, 249], ["an interaction term", "PROBLEM", 291, 310], ["HR", "TEST", 312, 314], ["CI", "TEST", 325, 327], ["p", "TEST", 339, 340]]], ["The coefficient direction suggests that mortality is proportionally higher in fitter patients.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["proportionally", "OBSERVATION_MODIFIER", 53, 67], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["Estimated in this way, the overall mortality attributable to COVID-19 was extremely high in this population (HR 213, 95% CI 24.6-1841, p < 0.01).", [["COVID", "TEST", 61, 66], ["HR", "TEST", 109, 111], ["CI", "TEST", 121, 123]]], ["When plotting mutually adjusted survival curves, tertiles of CFS showed distinct trajectories in non-COVID-19 controls, not at all apparent in COVID-19 cases (Fig. 1 ).", [["CFS", "DISEASE", 61, 64], ["survival curves", "TEST", 32, 47], ["tertiles of CFS", "TEST", 49, 64], ["distinct trajectories", "PROBLEM", 72, 93], ["non-COVID", "TEST", 97, 106], ["COVID", "TEST", 143, 148], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["trajectories", "OBSERVATION_MODIFIER", 81, 93]]], ["In keeping with the interaction parameter, differences were most stark in fitter patients (CFS 1-3) but less so in frailer ones (CFS 7-9).DiscussionIn this population of older admissions to a central London hospital, frailty did not appear to be associated with mortality rates after COVID-19.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["CFS", "TEST", 91, 94], ["CFS", "TEST", 129, 132], ["mortality rates", "TEST", 262, 277], ["COVID", "TEST", 284, 289]]], ["In addition, ecological measures of socioeconomic position were not associated with death, though there was some evidence of geater risk in South Asian compared with White populations.", [["death", "DISEASE", 84, 89], ["death", "PROBLEM", 84, 89], ["geater risk in South Asian", "PROBLEM", 125, 151]]], ["Associations with mortality in those with and without COVID-19 demonstrated much larger excess mortality in fitter, compared with frailer patients.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["COVID", "TEST", 54, 59]]], ["Taken together, our findings suggest that (1) frailty is not a good discriminator of prognosis in COVID-19 and (2) pathways to mortality may differ in fitter compared with frailer older patients.DiscussionOur results should be treated with caution.", [["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["caution", "TREATMENT", 240, 247]]], ["Data were collected from a single site, albeit a large teaching hospital at the first peak of the COVID-19 pandemic.", [["the COVID", "TEST", 94, 103], ["pandemic", "PROBLEM", 107, 115], ["large", "OBSERVATION_MODIFIER", 49, 54]]], ["Our results are only applicable to hospitalised patients, and some selection bias might arise from different indications for presenting to secondary care in COVID-19 patients versus those without respiratory symptoms (our controls).", [["respiratory", "ANATOMY", 196, 207], ["respiratory symptoms", "DISEASE", 196, 216], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 166, 174], ["respiratory symptoms", "PROBLEM", 196, 216]]], ["We used the Clinical Frailty Scale as the instrument recommended by NICE, but other frailty measures may have had different associations with mortality in the context of COVID-19.", [["the Clinical Frailty Scale", "TREATMENT", 8, 34], ["COVID", "TEST", 170, 175]]], ["Nonetheless, our data have the advantage of specialist assessments of COVID-19 status and frailty, as well as accurate statutory reporting of dates of death.", [["frailty", "DISEASE", 90, 97], ["death", "DISEASE", 151, 156], ["specialist assessments", "TEST", 44, 66], ["COVID", "TEST", 70, 75], ["death", "PROBLEM", 151, 156]]], ["These findings add to emerging reports quantifying the relationship between frailty and mortality in COVID-19.", [["frailty", "DISEASE", 76, 83], ["COVID", "TEST", 101, 106]]], ["In another London hospitalised cohort, crude deaths in COVID-19 were higher in patients who were frailer (median Clinical Frailty Scale score of 5 versus 4, p = 0.01) [13] .", [["deaths", "DISEASE", 45, 51], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["COVID", "TEST", 55, 60], ["Clinical Frailty Scale score", "TEST", 113, 141]]], ["Other UK case series have shown that patients who died without ventilatory support had a median Clinical Frailty Scale score of 7 [14] .", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["ventilatory support", "TREATMENT", 63, 82]]], ["To date, most studies are describing mortality without reference to a contemporaneous non-COVID-19 population, which would obscure the interaction apparent in our data.", [["a contemporaneous non-COVID", "TEST", 68, 95]]], ["In this respect, our findings are most consistent with comparable data from Leicester which also show no association between frailty and mortality in COVID-19 [15] .DiscussionOur findings have two major implications.", [["frailty", "DISEASE", 125, 132], ["COVID", "TEST", 150, 155], ["most consistent with", "UNCERTAINTY", 34, 54], ["no association", "UNCERTAINTY", 102, 116], ["major", "OBSERVATION_MODIFIER", 197, 202]]], ["First, if frailty states in COVID-19 are not associated with mortality, then this has only limited value as a consideration in older people who may require ventilatory support.", [["COVID-19", "CHEMICAL", 28, 36], ["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139], ["ventilatory support", "TREATMENT", 156, 175]]], ["This is in contrast to the central NICE guidance that recommends a frailty assessment as the first step in the assessment for critical care.", [["a frailty assessment", "TEST", 65, 85], ["the assessment", "TEST", 107, 121]]], ["Second, an interaction between COVID-19 and frailty implies that different pathways to death could be at play.", [["death", "DISEASE", 87, 92], ["COVID", "PROTEIN", 31, 36], ["COVID", "TEST", 31, 36]]], ["In general, the pathophysiology described in COVID-19 patients in critical care indicates substantial immune hyperactivation [16] .", [["COVID-19", "ORGANISM", 45, 53], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["COVID", "TEST", 45, 50], ["substantial immune hyperactivation", "PROBLEM", 90, 124], ["substantial", "OBSERVATION_MODIFIER", 90, 101], ["immune hyperactivation", "OBSERVATION", 102, 124]]], ["However, given survival in the CFS range 7-9 was similar in cases and controls, this may reflect death from COVID-19 is occurring in the same way as for other common illness and immune hyperactivation is unlikely to be a significant feature in this group.", [["CFS", "DISEASE", 31, 34], ["death", "DISEASE", 97, 102], ["COVID", "DISEASE", 108, 113], ["illness", "DISEASE", 166, 173], ["the CFS range", "TEST", 27, 40], ["death", "PROBLEM", 97, 102], ["COVID", "TEST", 108, 113], ["other common illness", "PROBLEM", 153, 173], ["immune hyperactivation", "PROBLEM", 178, 200], ["may reflect", "UNCERTAINTY", 85, 96]]], ["One might speculate that older people with frailty have pre-existing immunesenescence such that they are unable to mount excess immune responses and may be otherwise by dying from the direct effects of viral infection.DiscussionWhile COVID-19 clearly confers substantial mortality in older people, we show that this risk may arise for different reasons depending on pre-morbid frailty.", [["frailty", "DISEASE", 43, 50], ["viral infection", "DISEASE", 202, 217], ["people", "ORGANISM", 31, 37], ["people", "ORGANISM", 290, 296], ["people", "SPECIES", 31, 37], ["people", "SPECIES", 290, 296], ["viral infection", "PROBLEM", 202, 217], ["pre-morbid frailty", "PROBLEM", 366, 384], ["viral", "OBSERVATION_MODIFIER", 202, 207], ["infection", "OBSERVATION", 208, 217]]], ["Further work should consider other outcomes after COVID-19, particularly cognitive and physical function.", [["COVID", "TEST", 50, 55]]], ["If baseline frailty and associated immunesenescence influences the subsequent inflammatory response, this hints that different therapeutic strategies might be needed across the spectrum of frailty.", [["frailty", "DISEASE", 12, 19], ["immunesenescence", "DISEASE", 35, 51], ["frailty", "DISEASE", 189, 196], ["baseline frailty", "PROBLEM", 3, 19], ["the subsequent inflammatory response", "PROBLEM", 63, 99], ["different therapeutic strategies", "TREATMENT", 117, 149], ["frailty", "PROBLEM", 189, 196], ["inflammatory", "OBSERVATION_MODIFIER", 78, 90]]]], "5d82e40508a053474b654eacfd36812e3ac1b6e6": [["A c c e p t e d M a n u s c r i p t", [["u s", "TEST", 22, 25]]]], "a0da2385afc9fb7a9a6177abe87224397c4e9523": [["for the Down state protomer between the S1 subdomain, SD1, and the RBD domain of the same protomer that was completely missing in the Up state protomer analysis.", [["Down state protomer", "PROTEIN", 8, 27], ["S1 subdomain", "PROTEIN", 40, 52], ["SD1", "PROTEIN", 54, 57], ["RBD domain", "PROTEIN", 67, 77], ["Up state protomer", "PROTEIN", 134, 151], ["the RBD domain", "TEST", 63, 77], ["S1 subdomain", "ANATOMY", 40, 52], ["RBD", "OBSERVATION", 67, 70]]], ["Ironically, this dominant energetic interaction in the Down state protomer involved the backbone atoms of the same three residue sequence ALA520-PRO521-ALA522 of the RBD with the R-group of GLN564 in the SD1 domain.", [["RBD", "AMINO_ACID", 166, 169], ["GLN564", "SIMPLE_CHEMICAL", 190, 196], ["Down state protomer", "PROTEIN", 55, 74], ["ALA520", "PROTEIN", 138, 144], ["PRO521", "PROTEIN", 145, 151], ["ALA522", "PROTEIN", 152, 158], ["RBD", "PROTEIN", 166, 169], ["R-group", "PROTEIN", 179, 186], ["GLN564", "PROTEIN", 190, 196], ["SD1 domain", "PROTEIN", 204, 214], ["PRO521", "TEST", 145, 151], ["energetic interaction", "OBSERVATION", 26, 47], ["RBD", "OBSERVATION", 166, 169]]], ["Thus, this same three residue sequence acts as a stabilizer of the RBD in the Up conformation through its interactions with its neighboring NTD chain and a kind of latch in the Down state conformation through its interactions with its own SD1 domain.", [["RBD", "PROTEIN", 67, 70], ["Up conformation", "PROTEIN", 78, 93], ["NTD chain", "PROTEIN", 140, 149], ["SD1 domain", "PROTEIN", 239, 249], ["the RBD", "PROBLEM", 63, 70], ["RBD", "OBSERVATION", 67, 70]]], ["The dominant interaction energy residues identified here are also conserved across reported variations of SARS-Cov-2, as well as the closely related virions SARS-Cov and the bat corona virus RatG13.", [["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["bat corona virus", "ORGANISM", 174, 190], ["RatG13", "ORGANISM", 191, 197], ["SARS-Cov-2", "DNA", 106, 116], ["bat corona virus", "SPECIES", 174, 190], ["The dominant interaction energy residues", "PROBLEM", 0, 40], ["SARS", "PROBLEM", 106, 110], ["Cov", "TEST", 111, 114], ["the closely related virions SARS", "PROBLEM", 129, 161], ["dominant", "OBSERVATION_MODIFIER", 4, 12], ["interaction", "OBSERVATION", 13, 24], ["energy residues", "OBSERVATION", 25, 40]]], ["To help verify the potential latch for the Down state protomer, we conducted some preliminary molecular dynamic simulations that effectively turn off this specific latch glue point via a single point mutation of GLN564.", [["GLN564", "CHEMICAL", 212, 218], ["GLN564", "SIMPLE_CHEMICAL", 212, 218], ["Down state protomer", "PROTEIN", 43, 62], ["GLN564", "PROTEIN", 212, 218], ["the Down state protomer", "TREATMENT", 39, 62]]], ["Interestingly, the single point mutation lead to the latch releasing in less than a few nanoseconds, but the latch remained fixed in the wild state protomer for up to 0.1 microseconds that were simulated.", [["wild state protomer", "PROTEIN", 137, 156]]], ["Many more detailed studies are needed to understand the dynamics of the Up and Down states of the Spike protein, including the stabilizing chain-chain interactions and the mechanisms of transition from Down to Up state protomers.", [["Spike", "GENE_OR_GENE_PRODUCT", 98, 103], ["Spike protein", "PROTEIN", 98, 111], ["Up state protomers", "PROTEIN", 210, 228], ["the Spike protein", "TEST", 94, 111]]], ["Nonetheless, static dominant energy landscape mappings and preliminary molecular dynamic studies given here may represent a useful starting point for more detailed dynamic analyses and hopefully an improved understanding of the structure-function relationship of this highly complex protein associated with COVID-19.", [["COVID-19", "CHEMICAL", 307, 315], ["COVID-19", "GENE_OR_GENE_PRODUCT", 307, 315], ["highly complex protein", "PROTEIN", 268, 290], ["COVID-19", "PROTEIN", 307, 315], ["preliminary molecular dynamic studies", "TEST", 59, 96], ["COVID", "TEST", 307, 312]]]], "PMC5294970": [], "PMC7438844": [["IntroductionThe severe acute respiratory syndrome coronavirus2 (SARS-CoV2) causative agent of the coronavirus disease of 2019 (COVID-19), belongs to the coronaviridae family.", [["acute respiratory syndrome coronavirus2", "DISEASE", 23, 62], ["SARS-CoV2)", "DISEASE", 64, 74], ["coronavirus disease", "DISEASE", 98, 117], ["COVID-19", "CHEMICAL", 127, 135], ["SARS-CoV2", "ORGANISM", 64, 73], ["COVID-19", "ORGANISM", 127, 135], ["coronaviridae", "GENE_OR_GENE_PRODUCT", 153, 166], ["coronaviridae family", "PROTEIN", 153, 173], ["coronavirus", "SPECIES", 98, 109], ["severe acute respiratory syndrome coronavirus2 (SARS-CoV2)", "SPECIES", 16, 74], ["The severe acute respiratory syndrome coronavirus2", "PROBLEM", 12, 62], ["the coronavirus disease", "PROBLEM", 94, 117], ["COVID", "TEST", 127, 132], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndrome", "OBSERVATION", 29, 49], ["coronavirus disease", "OBSERVATION", 98, 117]]], ["The first outbreak of SARS-CoV2 infection is associated with the wet markets of Wuhan, China, suggesting the zoonotic origin of this virus (Mackenzie and Smith, 2020).", [["SARS-CoV2 infection", "DISEASE", 22, 41], ["SARS-CoV2", "ORGANISM", 22, 31], ["SARS", "PROBLEM", 22, 26], ["CoV2 infection", "PROBLEM", 27, 41], ["outbreak", "OBSERVATION_MODIFIER", 10, 18], ["SARS", "OBSERVATION", 22, 26], ["CoV2", "OBSERVATION_MODIFIER", 27, 31], ["infection", "OBSERVATION", 32, 41], ["zoonotic", "OBSERVATION_MODIFIER", 109, 117]]], ["Although SARS viruses are known to infect animals, in certain cases, the viruses may cross species barrier and infect humans (Rabi et al., 2020).", [["SARS viruses", "DISEASE", 9, 21], ["SARS viruses", "ORGANISM", 9, 21], ["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["SARS viruses", "SPECIES", 9, 21], ["humans", "SPECIES", 118, 124], ["SARS viruses", "PROBLEM", 9, 21], ["the viruses", "PROBLEM", 69, 80]]], ["Since the initial outbreak of COVID-19, it has become a serious threat to public health worldwide (Rabi et al., 2020).", [["COVID-19", "CHEMICAL", 30, 38], ["COVID", "TEST", 30, 35], ["serious", "OBSERVATION_MODIFIER", 56, 63]]], ["As of 5th July, 2020 COVID-19 has spread to more than 216 countries and territories, with 11,046,917 confirmed cases and 526,465 deaths across the globe.", [["deaths", "DISEASE", 129, 135], ["COVID", "TEST", 21, 26], ["globe", "ANATOMY", 147, 152]]], ["Nonetheless, European regions report 199,510 deaths with more than 2 million confirmed cases (WHO, 2020 COVID-19 dashboard, July 5th, 2020).IntroductionCOVID-19 symptoms majorly include breathing difficulty, lung infection, pneumonia, and fever (Aghagoli et al., 2020).", [["lung", "ANATOMY", 208, 212], ["deaths", "DISEASE", 45, 51], ["breathing difficulty", "DISEASE", 186, 206], ["lung infection", "DISEASE", 208, 222], ["pneumonia", "DISEASE", 224, 233], ["fever", "DISEASE", 239, 244], ["lung", "ORGAN", 208, 212], ["IntroductionCOVID", "TEST", 140, 157], ["symptoms", "PROBLEM", 161, 169], ["breathing difficulty", "PROBLEM", 186, 206], ["lung infection", "PROBLEM", 208, 222], ["pneumonia", "PROBLEM", 224, 233], ["fever", "PROBLEM", 239, 244], ["lung", "ANATOMY", 208, 212], ["infection", "OBSERVATION", 213, 222], ["pneumonia", "OBSERVATION", 224, 233]]], ["Emerging data depicts that COVID-19 patients have various aspects associated with hospitalization and severity.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["COVID", "TEST", 27, 32], ["severity", "PROBLEM", 102, 110]]], ["Nevertheless, the risk factors associated with SARS-CoV2 infection can be one or more such as cardiovascular diseases, hypertension, lung diseases, diabetes, etc. which may enhance susceptibility, complications, and mortality (Clerkin et al., 2020; Guo et al., 2020; Richardson et al., 2020; Yang et al., 2020).", [["cardiovascular", "ANATOMY", 94, 108], ["lung", "ANATOMY", 133, 137], ["SARS-CoV2 infection", "DISEASE", 47, 66], ["cardiovascular diseases", "DISEASE", 94, 117], ["hypertension", "DISEASE", 119, 131], ["lung diseases", "DISEASE", 133, 146], ["diabetes", "DISEASE", 148, 156], ["SARS-CoV2", "ORGANISM", 47, 56], ["lung", "ORGAN", 133, 137], ["the risk factors", "PROBLEM", 14, 30], ["SARS", "PROBLEM", 47, 51], ["CoV2 infection", "PROBLEM", 52, 66], ["cardiovascular diseases", "PROBLEM", 94, 117], ["hypertension", "PROBLEM", 119, 131], ["lung diseases", "PROBLEM", 133, 146], ["diabetes", "PROBLEM", 148, 156], ["complications", "PROBLEM", 197, 210], ["infection", "OBSERVATION", 57, 66], ["hypertension", "OBSERVATION", 119, 131], ["lung", "ANATOMY", 133, 137], ["diseases", "OBSERVATION", 138, 146], ["diabetes", "OBSERVATION", 148, 156]]], ["Interestingly, an increase in the number of COVID-19 patients with comorbidities is reported (Guo et al., 2020).", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 44, 49], ["comorbidities", "PROBLEM", 67, 80], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["number", "OBSERVATION_MODIFIER", 34, 40]]], ["The reasons for the exclusive relation of certain comorbidities with COVID-19 may be many.", [["COVID-19", "CHEMICAL", 69, 77], ["certain comorbidities", "PROBLEM", 42, 63], ["COVID", "TEST", 69, 74]]], ["It is reported that the virus attacks the smallest of the blood vessels\u2019 endothelial lining, thereby leading to circulation problems and impaired vessels functioning in various organs (Sardu et al., 2020).", [["blood vessels", "ANATOMY", 58, 71], ["endothelial lining", "ANATOMY", 73, 91], ["vessels", "ANATOMY", 146, 153], ["organs", "ANATOMY", 177, 183], ["impaired vessels functioning", "DISEASE", 137, 165], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 58, 71], ["endothelial lining", "TISSUE", 73, 91], ["vessels", "MULTI-TISSUE_STRUCTURE", 146, 153], ["organs", "ORGAN", 177, 183], ["the virus attacks", "PROBLEM", 20, 37], ["circulation problems", "PROBLEM", 112, 132], ["impaired vessels functioning in various organs", "PROBLEM", 137, 183], ["virus", "OBSERVATION", 24, 29], ["smallest", "OBSERVATION_MODIFIER", 42, 50], ["blood vessels", "ANATOMY", 58, 71], ["endothelial", "ANATOMY", 73, 84], ["lining", "ANATOMY_MODIFIER", 85, 91], ["circulation", "OBSERVATION_MODIFIER", 112, 123], ["impaired", "OBSERVATION_MODIFIER", 137, 145], ["vessels", "OBSERVATION", 146, 153], ["organs", "ANATOMY", 177, 183]]], ["This can also explain the high vulnerability of patients with comorbidities like hypertension, obesity, diabetes, and cardiovascular disease.", [["cardiovascular", "ANATOMY", 118, 132], ["hypertension", "DISEASE", 81, 93], ["obesity", "DISEASE", 95, 102], ["diabetes", "DISEASE", 104, 112], ["cardiovascular disease", "DISEASE", 118, 140], ["patients", "ORGANISM", 48, 56], ["cardiovascular", "ANATOMICAL_SYSTEM", 118, 132], ["patients", "SPECIES", 48, 56], ["comorbidities", "PROBLEM", 62, 75], ["hypertension", "PROBLEM", 81, 93], ["obesity", "PROBLEM", 95, 102], ["diabetes", "PROBLEM", 104, 112], ["cardiovascular disease", "PROBLEM", 118, 140], ["high vulnerability", "OBSERVATION_MODIFIER", 26, 44], ["hypertension", "OBSERVATION", 81, 93], ["obesity", "OBSERVATION", 95, 102], ["diabetes", "OBSERVATION", 104, 112], ["cardiovascular disease", "OBSERVATION", 118, 140]]], ["Besides, renal histopathological findings of COVID-19 patients show damaged endothelium (Su et al., 2020).", [["renal", "ANATOMY", 9, 14], ["endothelium", "ANATOMY", 76, 87], ["renal", "ORGAN", 9, 14], ["patients", "ORGANISM", 54, 62], ["endothelium", "TISSUE", 76, 87], ["patients", "SPECIES", 54, 62], ["COVID", "TEST", 45, 50], ["damaged endothelium", "PROBLEM", 68, 87], ["renal", "ANATOMY", 9, 14], ["histopathological", "OBSERVATION", 15, 32], ["damaged endothelium", "OBSERVATION", 68, 87]]], ["Additionally, studies have established the presence of inflammatory cells and viral elements within the endothelial cells of COVID-19 patients.", [["inflammatory cells", "ANATOMY", 55, 73], ["endothelial cells", "ANATOMY", 104, 121], ["inflammatory cells", "CELL", 55, 73], ["endothelial cells", "CELL", 104, 121], ["COVID-19", "CELL", 125, 133], ["patients", "ORGANISM", 134, 142], ["inflammatory cells", "CELL_TYPE", 55, 73], ["viral elements", "DNA", 78, 92], ["endothelial cells", "CELL_TYPE", 104, 121], ["patients", "SPECIES", 134, 142], ["studies", "TEST", 14, 21], ["inflammatory cells", "PROBLEM", 55, 73], ["viral elements", "PROBLEM", 78, 92], ["COVID", "TEST", 125, 130], ["inflammatory cells", "OBSERVATION", 55, 73], ["viral elements", "OBSERVATION", 78, 92], ["endothelial cells", "OBSERVATION", 104, 121]]], ["Bilateral diffuse alveolar damage with cellular fibromyxoid exudates and pulmonary oedema is observed in post-mortem samples of COVID-19 patients (Xu et al., 2020).", [["alveolar", "ANATOMY", 18, 26], ["cellular fibromyxoid exudates", "ANATOMY", 39, 68], ["pulmonary", "ANATOMY", 73, 82], ["post-mortem samples", "ANATOMY", 105, 124], ["alveolar damage", "DISEASE", 18, 33], ["pulmonary oedema", "DISEASE", 73, 89], ["alveolar", "MULTI-TISSUE_STRUCTURE", 18, 26], ["cellular", "CELL", 39, 47], ["fibromyxoid exudates", "TISSUE", 48, 68], ["pulmonary", "ORGAN", 73, 82], ["post-mortem samples", "CANCER", 105, 124], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["Bilateral diffuse alveolar damage", "PROBLEM", 0, 33], ["cellular fibromyxoid exudates", "PROBLEM", 39, 68], ["pulmonary oedema", "PROBLEM", 73, 89], ["diffuse", "OBSERVATION_MODIFIER", 10, 17], ["alveolar", "ANATOMY_MODIFIER", 18, 26], ["damage", "OBSERVATION", 27, 33], ["cellular", "OBSERVATION_MODIFIER", 39, 47], ["fibromyxoid exudates", "OBSERVATION", 48, 68], ["pulmonary", "ANATOMY", 73, 82], ["oedema", "OBSERVATION", 83, 89]]], ["Therefore, the multi-organ failure observed in COVID-19 may be due to damage to the endothelium caused by either direct virus infection or immune cells recruitment to the site of infection (Zaim et al., 2020).", [["multi-organ", "ANATOMY", 15, 26], ["endothelium", "ANATOMY", 84, 95], ["immune cells", "ANATOMY", 139, 151], ["site", "ANATOMY", 171, 175], ["multi-organ failure", "DISEASE", 15, 34], ["COVID-19", "CHEMICAL", 47, 55], ["damage to the endothelium", "DISEASE", 70, 95], ["infection", "DISEASE", 126, 135], ["infection", "DISEASE", 179, 188], ["COVID-19", "CHEMICAL", 47, 55], ["COVID-19", "GENE_OR_GENE_PRODUCT", 47, 55], ["endothelium", "TISSUE", 84, 95], ["immune cells", "CELL", 139, 151], ["immune cells", "CELL_TYPE", 139, 151], ["the multi-organ failure", "PROBLEM", 11, 34], ["COVID", "TEST", 47, 52], ["damage to the endothelium", "PROBLEM", 70, 95], ["direct virus infection", "PROBLEM", 113, 135], ["immune cells recruitment", "TREATMENT", 139, 163], ["infection", "PROBLEM", 179, 188], ["multi-organ", "ANATOMY", 15, 26], ["failure", "OBSERVATION", 27, 34], ["endothelium", "ANATOMY", 84, 95], ["immune cells", "OBSERVATION", 139, 151], ["infection", "OBSERVATION", 179, 188]]], ["Fascinating studies also suggest an enhanced death rate for COVID-19 patients who possess one of the comorbidities mentioned above.", [["death", "DISEASE", 45, 50], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Fascinating studies", "TEST", 0, 19], ["an enhanced death rate", "PROBLEM", 33, 55], ["the comorbidities", "PROBLEM", 97, 114], ["enhanced", "OBSERVATION_MODIFIER", 36, 44], ["death", "OBSERVATION", 45, 50], ["comorbidities", "OBSERVATION", 101, 114]]], ["A summarized report addressed that the overall case-fatality rate (2.3%) increased for COVID-19 patients with already prevailing comorbid conditions such as cardiovascular disease (10.5%), diabetes (7.3%), chronic respiratory disease (6.3%) and hypertension (6.0%) (Wu and McGoogan, 2020).", [["cardiovascular", "ANATOMY", 157, 171], ["respiratory", "ANATOMY", 214, 225], ["cardiovascular disease", "DISEASE", 157, 179], ["diabetes", "DISEASE", 189, 197], ["chronic respiratory disease", "DISEASE", 206, 233], ["hypertension", "DISEASE", 245, 257], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["fatality rate", "TEST", 52, 65], ["already prevailing comorbid conditions", "PROBLEM", 110, 148], ["cardiovascular disease", "PROBLEM", 157, 179], ["diabetes", "PROBLEM", 189, 197], ["chronic respiratory disease", "PROBLEM", 206, 233], ["hypertension", "PROBLEM", 245, 257], ["cardiovascular", "ANATOMY", 157, 171], ["chronic", "OBSERVATION_MODIFIER", 206, 213], ["respiratory disease", "OBSERVATION", 214, 233], ["hypertension", "OBSERVATION", 245, 257]]], ["A prospective cohort study related the prevalence of acute kidney injury in COVID-19 patients with in-hospital mortality (Cheng et al., 2020).", [["kidney", "ANATOMY", 59, 65], ["acute kidney injury", "DISEASE", 53, 72], ["kidney", "ORGAN", 59, 65], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["A prospective cohort study", "TEST", 0, 26], ["acute kidney injury", "PROBLEM", 53, 72], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["kidney", "ANATOMY", 59, 65], ["injury", "OBSERVATION", 66, 72]]], ["Moreover, considering various reports on COVID-19 comorbid hospitalized cases and deaths we quantitatively analyzed the relation of hospitalized cases and death reports with one or more comorbidities in this pandemic situation.IntroductionFurthermore, there might be a correlation between COVID-19 medications and deaths due to comorbidity in COVID-19.", [["deaths", "DISEASE", 82, 88], ["death", "DISEASE", 155, 160], ["deaths", "DISEASE", 314, 320], ["COVID-19 medications", "TREATMENT", 289, 309], ["comorbidity", "PROBLEM", 328, 339], ["COVID", "TEST", 343, 348]]], ["The medication regimen may vary among countries.", [["The medication regimen", "TREATMENT", 0, 22]]], ["Notably, it increases perplexity in this concern.", [["increases", "OBSERVATION_MODIFIER", 12, 21], ["perplexity", "OBSERVATION", 22, 32]]], ["Thus death reports associated with particular comorbidity may also vary among countries.", [["death", "DISEASE", 5, 10], ["particular comorbidity", "PROBLEM", 35, 57]]], ["Hence, there is a need for prudent selection of medication for COVID-19 patients with already prevailing comorbidities.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["prudent selection of medication", "TREATMENT", 27, 58], ["COVID", "TREATMENT", 63, 68], ["already prevailing comorbidities", "PROBLEM", 86, 118]]], ["Our study provides a glimpse of the need for repurposed COVID-19 drugs on associated comorbidity based on previous studies.", [["COVID-19", "CHEMICAL", 56, 64], ["Our study", "TEST", 0, 9], ["repurposed COVID-19 drugs", "TREATMENT", 45, 70], ["associated comorbidity", "PROBLEM", 74, 96], ["previous studies", "TEST", 106, 122]]], ["This may further help for better design of the COVID-19 medication regimen in patients with prevailing health conditions.Data Collection ::: Materials and MethodsWe acquired the data of COVID-19 patients with associated comorbidities from countries, namely France, Italy, Netherlands, Spain, and Sweden.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 195, 203], ["the COVID-19 medication regimen", "TREATMENT", 43, 74], ["COVID", "TEST", 186, 191], ["associated comorbidities", "PROBLEM", 209, 233]]], ["Namely, the open access portals of European Centre for Disease Prevention and Control (ECDC), French Public Health Agency, Italian National Institute of Health, National Institute of Public Health and the Environment Netherlands, The Institute of Health Carlos III Spain, The Public Health Agency of Sweden have been accessed.", [["Disease Prevention", "TREATMENT", 55, 73]]], ["The information about numbers of hospitalized or deceased COVID-19 patients with associated comorbidities from individual countries was already provided in their respective reports.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["associated comorbidities", "PROBLEM", 81, 105]]], ["We selected, assembled, and categorized the data based on hospitalized and deceased COVID-19 patients with associated comorbidities in Table 1.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101]]], ["One patient may have been included in more than one comorbidity group.Data Collection ::: Materials and MethodsThe retrieved data ranges within a time interval until 23rd April 2020.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Methods", "TREATMENT", 104, 111]]], ["Specifically, for France, Netherlands, Spain, and Sweden the timespan for hospitalized as well as death data was 16/03/2020 to 21/04/2020, 27/02/2020 to 10/04/2020, 31/01/2020 to 22/04/2020 and 13/04/2020 to 19/04/2020, respectively.", [["death", "DISEASE", 98, 103], ["death data", "TEST", 98, 108]]], ["In the case of France, the data for comorbidities like hypertension and liver diseases was available for 16/03/2020 to 04/04/2020 period only.", [["liver", "ANATOMY", 72, 77], ["hypertension", "DISEASE", 55, 67], ["liver diseases", "DISEASE", 72, 86], ["liver", "ORGAN", 72, 77], ["comorbidities", "PROBLEM", 36, 49], ["hypertension", "PROBLEM", 55, 67], ["liver diseases", "PROBLEM", 72, 86], ["hypertension", "OBSERVATION", 55, 67], ["liver", "ANATOMY", 72, 77], ["diseases", "OBSERVATION", 78, 86]]], ["For Italy, the deceased patient\u2019s data was obtained from the report of the Italian National Institute of Health, the timespan for which was 21/02/2020 to 23/04/2020.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31]]], ["The hospitalized patients data was absent in this report, so it has been obtained from ECDC rapid risk assessment report 8th update on COVID-19 where timespan for patient\u2019s data is not available.", [["patients", "ORGANISM", 17, 25], ["patient", "ORGANISM", 163, 170], ["patients", "SPECIES", 17, 25], ["patient", "SPECIES", 163, 170], ["COVID", "TEST", 135, 140], ["patient\u2019s data", "TEST", 163, 177]]], ["We have also verified this translation results using other platforms like Bing Microsoft Translator, 20202 and Yandex.Translate, 20203.Data Collection ::: Materials and MethodsWe performed a literature survey for adverse effects of medications generally given to individuals with included comorbidities or for COVID-19 treatments.", [["medications", "TREATMENT", 232, 243], ["comorbidities", "PROBLEM", 289, 302], ["COVID-19 treatments", "TREATMENT", 310, 329]]], ["These medications and their possible mechanism have been included in Table 2.Statistical Analysis ::: Materials and MethodsA two-sample t-test between the proportions of hospitalized and deceased patients with various comorbidities (heart diseases, diabetes, kidney, liver diseases, immunodeficiency, and neurological disorders) from different countries (France, Italy, Netherlands, Spain, and Sweden) was performed separately to determine whether there was a significant difference between hospitalized patients and the subsequent deaths due to particular comorbidity with respect to the percent of affected individuals in the respective country.", [["heart", "ANATOMY", 233, 238], ["kidney", "ANATOMY", 259, 265], ["liver", "ANATOMY", 267, 272], ["neurological", "ANATOMY", 305, 317], ["heart diseases", "DISEASE", 233, 247], ["diabetes", "DISEASE", 249, 257], ["kidney, liver diseases", "DISEASE", 259, 281], ["immunodeficiency", "DISEASE", 283, 299], ["neurological disorders", "DISEASE", 305, 327], ["deaths", "DISEASE", 532, 538], ["patients", "ORGANISM", 196, 204], ["heart", "ORGAN", 233, 238], ["kidney", "ORGAN", 259, 265], ["liver", "ORGAN", 267, 272], ["patients", "ORGANISM", 504, 512], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 504, 512], ["These medications", "TREATMENT", 0, 17], ["MethodsA", "TEST", 116, 124], ["sample t-test", "TEST", 129, 142], ["various comorbidities", "PROBLEM", 210, 231], ["heart diseases", "PROBLEM", 233, 247], ["diabetes", "PROBLEM", 249, 257], ["kidney, liver diseases", "PROBLEM", 259, 281], ["immunodeficiency", "PROBLEM", 283, 299], ["neurological disorders", "PROBLEM", 305, 327], ["particular comorbidity", "PROBLEM", 546, 568], ["heart", "ANATOMY", 233, 238], ["diseases", "OBSERVATION", 239, 247], ["kidney", "ANATOMY", 259, 265], ["liver", "ANATOMY", 267, 272], ["immunodeficiency", "OBSERVATION", 283, 299], ["significant", "OBSERVATION_MODIFIER", 460, 471]]], ["The t-statistic was significant at the 0.05 critical alpha level, p < 0.05 at CI-95%.ResultsThe number of hospitalized COVID-19 patients with at least one comorbidity along with the death reports, as a consequence of the disease, from various countries is enlisted in Table 1.", [["death", "DISEASE", 182, 187], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["CI", "TEST", 78, 80], ["the disease", "PROBLEM", 217, 228], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["disease", "OBSERVATION", 221, 228]]], ["The death proportions due to Heart Diseases including, cardiovascular diseases and hypertension, were significantly higher (p < 0.0001) compared to the total hospitalized patients in Italy, Sweden, and Spain.", [["Heart", "ANATOMY", 29, 34], ["cardiovascular", "ANATOMY", 55, 69], ["death", "DISEASE", 4, 9], ["Heart Diseases", "DISEASE", 29, 43], ["cardiovascular diseases", "DISEASE", 55, 78], ["hypertension", "DISEASE", 83, 95], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["The death proportions", "PROBLEM", 0, 21], ["Heart Diseases", "PROBLEM", 29, 43], ["cardiovascular diseases", "PROBLEM", 55, 78], ["hypertension", "PROBLEM", 83, 95], ["Heart", "ANATOMY", 29, 34], ["Diseases", "OBSERVATION", 35, 43], ["cardiovascular", "ANATOMY", 55, 69], ["diseases", "OBSERVATION", 70, 78], ["hypertension", "OBSERVATION", 83, 95], ["significantly", "OBSERVATION_MODIFIER", 102, 115], ["higher", "OBSERVATION_MODIFIER", 116, 122]]], ["Although the proportion of death reports with respect to hospitalized patients is higher while not significant (p = 0.1468) for the Netherlands.", [["death", "DISEASE", 27, 32], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["In addition, the estimated deaths due to cardiovascular diseases are significantly (p < 0.0001) higher than hypertension (p = 0.231) in France.", [["cardiovascular", "ANATOMY", 41, 55], ["deaths", "DISEASE", 27, 33], ["cardiovascular diseases", "DISEASE", 41, 64], ["hypertension", "DISEASE", 108, 120], ["the estimated deaths", "PROBLEM", 13, 33], ["cardiovascular diseases", "PROBLEM", 41, 64], ["hypertension", "PROBLEM", 108, 120], ["cardiovascular", "ANATOMY", 41, 55], ["diseases", "OBSERVATION", 56, 64]]], ["The population of deceased diabetic patients to hospitalized patients is highly significant (p < 0.0001) in Italy and Spain, unlike the Netherlands (p = 0.3906) and Sweden (p = 0.5814).", [["diabetic", "DISEASE", 27, 35], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 61, 69], ["significant", "OBSERVATION_MODIFIER", 80, 91]]], ["However, France shows significance in death reports due to diabetes (p = 0.0134) compared to the hospitalized population.", [["death", "DISEASE", 38, 43], ["diabetes", "DISEASE", 59, 67], ["death", "PROBLEM", 38, 43], ["diabetes", "PROBLEM", 59, 67]]], ["Furthermore, lung diseases being most widely associated with COVID-19 death influence a majority of individuals in various countries.", [["lung", "ANATOMY", 13, 17], ["lung diseases", "DISEASE", 13, 26], ["death", "DISEASE", 70, 75], ["lung", "ORGAN", 13, 17], ["lung diseases", "PROBLEM", 13, 26], ["COVID-19 death", "PROBLEM", 61, 75], ["lung", "ANATOMY", 13, 17], ["diseases", "OBSERVATION", 18, 26]]], ["However, the deaths due to lung disorders are significantly higher compared to those hospitalized in countries like Italy (p < 0.0001), Spain (p < 0.0001), France (p = 0.0007), and Sweden (p = 0.0492).", [["lung", "ANATOMY", 27, 31], ["deaths", "DISEASE", 13, 19], ["lung disorders", "DISEASE", 27, 41], ["lung", "ORGAN", 27, 31], ["lung disorders", "PROBLEM", 27, 41], ["lung", "ANATOMY", 27, 31], ["disorders", "OBSERVATION", 32, 41], ["significantly", "OBSERVATION_MODIFIER", 46, 59], ["higher", "OBSERVATION_MODIFIER", 60, 66]]], ["Further, the Netherlands has higher while no significant (p = 0.4008) deaths due to chronic lung disorder compared to hospitalized patients.", [["lung", "ANATOMY", 92, 96], ["deaths", "DISEASE", 70, 76], ["chronic lung disorder", "DISEASE", 84, 105], ["lung", "ORGAN", 92, 96], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["chronic lung disorder", "PROBLEM", 84, 105], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["no", "UNCERTAINTY", 42, 44], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["lung", "ANATOMY", 92, 96], ["disorder", "OBSERVATION", 97, 105]]], ["Moreover, deaths due to kidney diseases (Italy- p < 0.0001; Sweden- p < 0.0001; Netherlands- p = 0.0001; France- p = 0.0033) and neurological ailments (France- p = 0.0001; Netherlands- p < 0.0001) is greater than the total hospitalized patients affected by the particular comorbidity in these countries.", [["kidney", "ANATOMY", 24, 30], ["neurological", "ANATOMY", 129, 141], ["deaths", "DISEASE", 10, 16], ["kidney diseases (Italy- p < 0.0001; Sweden- p < 0.0001; Netherlands- p = 0.0001; France- p = 0.0033) and neurological ailments", "DISEASE", 24, 150], ["kidney", "ORGAN", 24, 30], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["kidney diseases", "PROBLEM", 24, 39], ["neurological ailments", "TEST", 129, 150], ["kidney", "ANATOMY", 24, 30], ["diseases", "OBSERVATION", 31, 39]]], ["We obtain a significant population of immunodeficient patients dead compared to hospitalized patients in France (p = 0.0264).", [["immunodeficient", "ORGANISM", 38, 53], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 93, 101], ["immunodeficient patients dead", "PROBLEM", 38, 67], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["population", "OBSERVATION_MODIFIER", 24, 34], ["immunodeficient", "OBSERVATION", 38, 53]]], ["On the contrary, we have seen a significant reduction in the number of immunodeficient deceased individuals compared to the total hospital admitted population in the Netherlands (p = 0.0058).", [["a significant reduction", "PROBLEM", 30, 53], ["immunodeficient deceased individuals", "PROBLEM", 71, 107], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["number", "OBSERVATION_MODIFIER", 61, 67], ["immunodeficient", "OBSERVATION", 71, 86]]], ["Also, immunodeficiency seems to have no effect with respect to mortality on the hospitalized patients of Sweden (p = 1).", [["immunodeficiency", "DISEASE", 6, 22], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["immunodeficiency", "PROBLEM", 6, 22], ["immunodeficiency", "OBSERVATION", 6, 22]]], ["Deaths due to Liver diseases are least affected by SARS-CoV2 infection compared to other comorbidities under investigation.", [["Liver", "ANATOMY", 14, 19], ["Liver diseases", "DISEASE", 14, 28], ["SARS-CoV2 infection", "DISEASE", 51, 70], ["Liver", "ORGAN", 14, 19], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 51, 60], ["Liver diseases", "PROBLEM", 14, 28], ["SARS", "PROBLEM", 51, 55], ["CoV2 infection", "PROBLEM", 56, 70], ["Liver", "ANATOMY", 14, 19], ["diseases", "OBSERVATION", 20, 28], ["SARS", "OBSERVATION_MODIFIER", 51, 55], ["infection", "OBSERVATION", 61, 70]]], ["The deaths due to liver diseases are not statistically significant compared to the total hospitalized patients for the same comorbidity (Italy- p = 0.1619; Netherlands- p = 1; Sweden- p = 1).ResultsIn Table 2, the drugs which are used to treat the particular comorbidity or for COVID-19 treatment and further the possible adverse outcomes are enlisted.", [["liver", "ANATOMY", 18, 23], ["deaths", "DISEASE", 4, 10], ["liver diseases", "DISEASE", 18, 32], ["liver", "ORGAN", 18, 23], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["The deaths", "PROBLEM", 0, 10], ["liver diseases", "PROBLEM", 18, 32], ["the drugs", "TREATMENT", 210, 219], ["the particular comorbidity", "PROBLEM", 244, 270], ["COVID-19 treatment", "TREATMENT", 278, 296], ["adverse outcomes", "PROBLEM", 322, 338], ["liver", "ANATOMY", 18, 23], ["diseases", "OBSERVATION", 24, 32]]], ["Mainly the drugs were Losartan and other ACE inhibitors (ACEi), angiotensin-receptor blockers (ARBS), Chloroquine, Hydroxychloroquine, Ruxolitinib, Remdesivir, and Tocilizumab.", [["Losartan", "CHEMICAL", 22, 30], ["ACEi", "CHEMICAL", 57, 61], ["angiotensin", "CHEMICAL", 64, 75], ["ARBS", "CHEMICAL", 95, 99], ["Chloroquine", "CHEMICAL", 102, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Ruxolitinib", "CHEMICAL", 135, 146], ["Remdesivir", "CHEMICAL", 148, 158], ["Tocilizumab", "CHEMICAL", 164, 175], ["Losartan", "CHEMICAL", 22, 30], ["Chloroquine", "CHEMICAL", 102, 113], ["Hydroxychloroquine", "CHEMICAL", 115, 133], ["Ruxolitinib", "CHEMICAL", 135, 146], ["Remdesivir", "CHEMICAL", 148, 158], ["Tocilizumab", "CHEMICAL", 164, 175], ["Losartan", "SIMPLE_CHEMICAL", 22, 30], ["ACE", "GENE_OR_GENE_PRODUCT", 41, 44], ["ACEi", "SIMPLE_CHEMICAL", 57, 61], ["angiotensin-receptor blockers", "SIMPLE_CHEMICAL", 64, 93], ["ARBS", "SIMPLE_CHEMICAL", 95, 99], ["Chloroquine", "SIMPLE_CHEMICAL", 102, 113], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 115, 133], ["Ruxolitinib", "SIMPLE_CHEMICAL", 135, 146], ["Remdesivir", "SIMPLE_CHEMICAL", 148, 158], ["Tocilizumab", "SIMPLE_CHEMICAL", 164, 175], ["the drugs", "TREATMENT", 7, 16], ["Losartan", "TREATMENT", 22, 30], ["other ACE inhibitors", "TREATMENT", 35, 55], ["ACEi", "TREATMENT", 57, 61], ["angiotensin-receptor blockers", "TREATMENT", 64, 93], ["ARBS", "TREATMENT", 95, 99], ["Chloroquine", "TREATMENT", 102, 113], ["Hydroxychloroquine", "TREATMENT", 115, 133], ["Ruxolitinib", "TREATMENT", 135, 146], ["Remdesivir", "TREATMENT", 148, 158], ["Tocilizumab", "TREATMENT", 164, 175]]], ["Surprisingly, most of the drugs were affecting patients with cardiovascular diseases and hypertension, followed by diabetes, kidney, and neurological diseases.DiscussionAccording to a study, approximately 25% of COVID-19 positive people had at least one comorbidity associated (Guan et al., 2020).", [["cardiovascular", "ANATOMY", 61, 75], ["kidney", "ANATOMY", 125, 131], ["neurological", "ANATOMY", 137, 149], ["cardiovascular diseases", "DISEASE", 61, 84], ["hypertension", "DISEASE", 89, 101], ["diabetes, kidney, and neurological diseases", "DISEASE", 115, 158], ["patients", "ORGANISM", 47, 55], ["cardiovascular", "ANATOMICAL_SYSTEM", 61, 75], ["kidney", "ORGAN", 125, 131], ["people", "ORGANISM", 230, 236], ["patients", "SPECIES", 47, 55], ["people", "SPECIES", 230, 236], ["cardiovascular diseases", "PROBLEM", 61, 84], ["hypertension", "PROBLEM", 89, 101], ["diabetes", "PROBLEM", 115, 123], ["kidney, and neurological diseases", "PROBLEM", 125, 158], ["a study", "TEST", 182, 189], ["COVID", "TEST", 212, 217], ["hypertension", "OBSERVATION", 89, 101], ["kidney", "ANATOMY", 125, 131], ["neurological diseases", "OBSERVATION", 137, 158]]], ["The major COVID-19 related comorbidities, namely hypertension, cardiovascular diseases, diabetes, kidney diseases, and neurological complications in various countries, are evaluated in the present article.", [["cardiovascular", "ANATOMY", 63, 77], ["kidney", "ANATOMY", 98, 104], ["neurological", "ANATOMY", 119, 131], ["hypertension", "DISEASE", 49, 61], ["cardiovascular diseases", "DISEASE", 63, 86], ["diabetes", "DISEASE", 88, 96], ["kidney diseases", "DISEASE", 98, 113], ["neurological complications", "DISEASE", 119, 145], ["kidney", "ORGAN", 98, 104], ["hypertension", "PROBLEM", 49, 61], ["cardiovascular diseases", "PROBLEM", 63, 86], ["diabetes", "PROBLEM", 88, 96], ["kidney diseases", "PROBLEM", 98, 113], ["neurological complications in various countries", "PROBLEM", 119, 166], ["hypertension", "OBSERVATION", 49, 61], ["cardiovascular diseases", "OBSERVATION", 63, 86], ["diabetes", "OBSERVATION", 88, 96], ["kidney", "ANATOMY", 98, 104], ["diseases", "OBSERVATION", 105, 113], ["neurological", "OBSERVATION_MODIFIER", 119, 131], ["complications", "OBSERVATION", 132, 145]]], ["In addition, the majority of the dysfunctions mentioned above are often associated with endothelial deterioration, indicating that endothelium can be the target of SARS-CoV2 (Chen et al., 2020).DiscussionOur study reveals that the country-wide pattern of COVID-19 associated comorbidities in hospitalized and deceased patients remains evidently similar (Table 1).", [["endothelial", "ANATOMY", 88, 99], ["endothelium", "ANATOMY", 131, 142], ["SARS", "DISEASE", 164, 168], ["endothelial", "CELL", 88, 99], ["endothelium", "TISSUE", 131, 142], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 164, 173], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["the dysfunctions", "PROBLEM", 29, 45], ["endothelial deterioration", "PROBLEM", 88, 113], ["DiscussionOur study", "TEST", 194, 213], ["COVID-19 associated comorbidities", "PROBLEM", 255, 288], ["majority", "OBSERVATION_MODIFIER", 17, 25], ["dysfunctions", "OBSERVATION", 33, 45], ["endothelial", "ANATOMY", 88, 99], ["deterioration", "OBSERVATION", 100, 113]]], ["Notably we found that heart diseases, including hypertension along with cardiovascular diseases, are the most frequent association with SARS-CoV2 infection in most countries (Italy, France, Spain, and Sweden) except the Netherlands.", [["heart", "ANATOMY", 22, 27], ["cardiovascular", "ANATOMY", 72, 86], ["heart diseases", "DISEASE", 22, 36], ["hypertension", "DISEASE", 48, 60], ["cardiovascular diseases", "DISEASE", 72, 95], ["SARS-CoV2 infection", "DISEASE", 136, 155], ["heart", "ORGAN", 22, 27], ["heart diseases", "PROBLEM", 22, 36], ["hypertension", "PROBLEM", 48, 60], ["cardiovascular diseases", "PROBLEM", 72, 95], ["SARS", "PROBLEM", 136, 140], ["CoV2 infection", "PROBLEM", 141, 155], ["heart", "ANATOMY", 22, 27], ["diseases", "OBSERVATION", 28, 36], ["hypertension", "OBSERVATION", 48, 60], ["cardiovascular diseases", "OBSERVATION", 72, 95], ["SARS", "OBSERVATION", 136, 140], ["infection", "OBSERVATION", 146, 155]]], ["Similar reports of a high prevalence of cardiovascular disease and hypertension among hospitalized and diseased patients were demonstrated by Richardson et al. (2020), Wu and McGoogan (2020), and Zhou et al., 2020 in case reports from China and the United States, respectively.", [["cardiovascular", "ANATOMY", 40, 54], ["cardiovascular disease", "DISEASE", 40, 62], ["hypertension", "DISEASE", 67, 79], ["cardiovascular", "ANATOMICAL_SYSTEM", 40, 54], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["cardiovascular disease", "PROBLEM", 40, 62], ["hypertension", "PROBLEM", 67, 79], ["high", "OBSERVATION_MODIFIER", 21, 25], ["cardiovascular disease", "OBSERVATION", 40, 62], ["hypertension", "OBSERVATION", 67, 79]]], ["Importantly, SARS-CoV2 associated pneumonia in heart patients may develop hypoxemia due to hindrance in gas exchange (Li B. et al., 2020).", [["heart", "ANATOMY", 47, 52], ["SARS", "DISEASE", 13, 17], ["pneumonia", "DISEASE", 34, 43], ["hypoxemia", "DISEASE", 74, 83], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 13, 22], ["heart", "ORGAN", 47, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["pneumonia", "PROBLEM", 34, 43], ["hypoxemia", "PROBLEM", 74, 83], ["hindrance in gas exchange", "PROBLEM", 91, 116], ["pneumonia", "OBSERVATION", 34, 43], ["heart", "ANATOMY", 47, 52], ["hypoxemia", "OBSERVATION", 74, 83], ["gas exchange", "OBSERVATION", 104, 116]]], ["This may drive complications in cardiac functions and increase the risk of death.", [["cardiac", "ANATOMY", 32, 39], ["death", "DISEASE", 75, 80], ["cardiac", "ORGAN", 32, 39], ["complications in cardiac functions", "PROBLEM", 15, 49], ["death", "PROBLEM", 75, 80]]], ["Interestingly, our study depicts a profound proportion of deaths due to heart diseases, including cardiovascular diseases and hypertension.", [["heart", "ANATOMY", 72, 77], ["cardiovascular", "ANATOMY", 98, 112], ["deaths", "DISEASE", 58, 64], ["heart diseases", "DISEASE", 72, 86], ["cardiovascular diseases", "DISEASE", 98, 121], ["hypertension", "DISEASE", 126, 138], ["heart", "ORGAN", 72, 77], ["cardiovascular", "ANATOMICAL_SYSTEM", 98, 112], ["our study", "TEST", 15, 24], ["heart diseases", "PROBLEM", 72, 86], ["cardiovascular diseases", "PROBLEM", 98, 121], ["hypertension", "PROBLEM", 126, 138], ["heart", "ANATOMY", 72, 77], ["diseases", "OBSERVATION", 78, 86], ["cardiovascular", "ANATOMY", 98, 112], ["diseases", "OBSERVATION", 113, 121], ["hypertension", "OBSERVATION", 126, 138]]], ["Also, our investigation reflects that the majority of the drugs used in the case of COVID-19 treatment are related to heart ailments, such as cardiovascular diseases and hypertension (Table 2).", [["heart", "ANATOMY", 118, 123], ["cardiovascular", "ANATOMY", 142, 156], ["COVID-19", "CHEMICAL", 84, 92], ["heart ailments", "DISEASE", 118, 132], ["cardiovascular diseases", "DISEASE", 142, 165], ["hypertension", "DISEASE", 170, 182], ["COVID-19", "CHEMICAL", 84, 92], ["heart", "ORGAN", 118, 123], ["our investigation", "TEST", 6, 23], ["the drugs", "TREATMENT", 54, 63], ["COVID-19 treatment", "TREATMENT", 84, 102], ["heart ailments", "PROBLEM", 118, 132], ["cardiovascular diseases", "PROBLEM", 142, 165], ["hypertension", "PROBLEM", 170, 182], ["heart", "ANATOMY", 118, 123], ["ailments", "OBSERVATION", 124, 132], ["hypertension", "OBSERVATION", 170, 182]]], ["Further, ACE2, serine protease 2 (TMPRSS2), basigin (CD147), cathepsin B and L and sialic acid receptor expressed by the endothelial cells are used by SARS-CoV2 to gain entry into the host (Sardu et al., 2020).", [["endothelial cells", "ANATOMY", 121, 138], ["sialic acid", "CHEMICAL", 83, 94], ["serine", "CHEMICAL", 15, 21], ["sialic acid", "CHEMICAL", 83, 94], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["serine protease 2", "GENE_OR_GENE_PRODUCT", 15, 32], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 34, 41], ["basigin", "GENE_OR_GENE_PRODUCT", 44, 51], ["CD147", "GENE_OR_GENE_PRODUCT", 53, 58], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 61, 72], ["L", "GENE_OR_GENE_PRODUCT", 77, 78], ["sialic acid receptor", "GENE_OR_GENE_PRODUCT", 83, 103], ["endothelial cells", "CELL", 121, 138], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 151, 160], ["ACE2", "PROTEIN", 9, 13], ["serine protease 2", "PROTEIN", 15, 32], ["TMPRSS2", "PROTEIN", 34, 41], ["basigin", "PROTEIN", 44, 51], ["CD147", "PROTEIN", 53, 58], ["cathepsin B", "PROTEIN", 61, 72], ["L", "PROTEIN", 77, 78], ["sialic acid receptor", "PROTEIN", 83, 103], ["endothelial cells", "CELL_TYPE", 121, 138], ["ACE2", "TEST", 9, 13], ["serine protease", "TREATMENT", 15, 30], ["TMPRSS2", "TEST", 34, 41], ["basigin (CD147", "TREATMENT", 44, 58], ["cathepsin B and L and sialic acid receptor", "TREATMENT", 61, 103], ["the endothelial cells", "TREATMENT", 117, 138], ["endothelial cells", "OBSERVATION", 121, 138]]], ["Besides, ACEi/ARBs exert protective effects on patients with hypertension and heart disorders; however, the effect diminishes on the binding of virus spike protein to ACE2 (Sardu et al., 2020).", [["heart", "ANATOMY", 78, 83], ["ACEi", "CHEMICAL", 9, 13], ["ARBs", "CHEMICAL", 14, 18], ["hypertension", "DISEASE", 61, 73], ["heart disorders", "DISEASE", 78, 93], ["ACEi", "SIMPLE_CHEMICAL", 9, 13], ["ARBs", "SIMPLE_CHEMICAL", 14, 18], ["patients", "ORGANISM", 47, 55], ["heart", "ORGAN", 78, 83], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["virus spike protein", "PROTEIN", 144, 163], ["ACE2", "PROTEIN", 167, 171], ["patients", "SPECIES", 47, 55], ["ACEi", "TREATMENT", 9, 13], ["ARBs", "TREATMENT", 14, 18], ["hypertension", "PROBLEM", 61, 73], ["heart disorders", "PROBLEM", 78, 93], ["ACE2", "TEST", 167, 171], ["hypertension", "OBSERVATION", 61, 73], ["heart", "ANATOMY", 78, 83], ["disorders", "OBSERVATION", 84, 93]]], ["Chloroquine and Hydroxychloroquine, widely used drugs for SARS-CoV2 infection, were also reported to induce arrhythmias along with atrial and ventricular antiarrhythmic effects (Teixeira et al., 2002; Malviya, 2020).", [["atrial", "ANATOMY", 131, 137], ["ventricular", "ANATOMY", 142, 153], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxychloroquine", "CHEMICAL", 16, 34], ["SARS-CoV2 infection", "DISEASE", 58, 77], ["arrhythmias", "DISEASE", 108, 119], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["SARS-CoV2", "ORGANISM", 58, 67], ["atrial", "MULTI-TISSUE_STRUCTURE", 131, 137], ["ventricular", "MULTI-TISSUE_STRUCTURE", 142, 153], ["Chloroquine", "TREATMENT", 0, 11], ["Hydroxychloroquine", "TREATMENT", 16, 34], ["drugs", "TREATMENT", 48, 53], ["SARS", "PROBLEM", 58, 62], ["CoV2 infection", "PROBLEM", 63, 77], ["arrhythmias", "PROBLEM", 108, 119], ["atrial and ventricular antiarrhythmic effects", "PROBLEM", 131, 176], ["atrial", "ANATOMY", 131, 137], ["ventricular", "ANATOMY", 142, 153], ["antiarrhythmic", "OBSERVATION", 154, 168]]], ["Intriguingly reports from government medicine agencies of most of the countries like Italy, Spain, and France (Italian Medicines Agency, 2020; National Agency for the Safety of Medicines and Health Products, 2020; Spanish Agency for Medicines and Health Products, 2020) have earlier advised the use of Chloroquine and Hydroxychloroquine against COVID-19.DiscussionFurther, the virus is known to initiate diabetes by intensifying the condition of insulin resistance or by targeting the pancreatic islets.", [["pancreatic islets", "ANATOMY", 485, 502], ["Chloroquine", "CHEMICAL", 302, 313], ["Hydroxychloroquine", "CHEMICAL", 318, 336], ["COVID-19", "CHEMICAL", 345, 353], ["diabetes", "DISEASE", 404, 412], ["Chloroquine", "CHEMICAL", 302, 313], ["Hydroxychloroquine", "CHEMICAL", 318, 336], ["COVID-19", "CHEMICAL", 345, 353], ["Chloroquine", "SIMPLE_CHEMICAL", 302, 313], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 318, 336], ["insulin", "GENE_OR_GENE_PRODUCT", 446, 453], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 485, 502], ["pancreatic islets", "CELL_TYPE", 485, 502], ["Chloroquine", "TREATMENT", 302, 313], ["Hydroxychloroquine", "TREATMENT", 318, 336], ["COVID", "TREATMENT", 345, 350], ["the virus", "PROBLEM", 373, 382], ["diabetes", "PROBLEM", 404, 412], ["insulin resistance", "TREATMENT", 446, 464], ["insulin resistance", "OBSERVATION", 446, 464], ["pancreatic", "ANATOMY", 485, 495]]], ["ACE2 can serve as a therapeutic target and may aid in microcirculation in the islets (Sardu et al., 2020).", [["islets", "ANATOMY", 78, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["islets", "MULTI-TISSUE_STRUCTURE", 78, 84], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4]]], ["Several studies have already demonstrated that diabetic patients have increased susceptibility to COVID-19 (Remuzzi and Remuzzi, 2020).", [["diabetic", "DISEASE", 47, 55], ["COVID-19", "CHEMICAL", 98, 106], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Several studies", "TEST", 0, 15], ["increased susceptibility", "PROBLEM", 70, 94], ["COVID", "TEST", 98, 103], ["diabetic", "OBSERVATION", 47, 55], ["increased", "OBSERVATION_MODIFIER", 70, 79]]], ["Nevertheless, our study shows that the population of deceased diabetic patients to the total hospitalized patients with diabetes is higher in Italy and Spain, unlike the Netherlands and Sweden.DiscussionA case report of 5700 SARS-CoV2 infected patients from New York have reported an association of chronic lung disorders with COVID-19 (Richardson et al., 2020).", [["lung", "ANATOMY", 307, 311], ["diabetic", "DISEASE", 62, 70], ["diabetes", "DISEASE", 120, 128], ["SARS-CoV2 infected", "DISEASE", 225, 243], ["chronic lung disorders", "DISEASE", 299, 321], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 106, 114], ["SARS-CoV2", "ORGANISM", 225, 234], ["patients", "ORGANISM", 244, 252], ["lung", "ORGAN", 307, 311], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 244, 252], ["our study", "TEST", 14, 23], ["diabetes", "PROBLEM", 120, 128], ["chronic lung disorders", "PROBLEM", 299, 321], ["diabetes", "OBSERVATION", 120, 128], ["higher", "OBSERVATION_MODIFIER", 132, 138], ["chronic", "OBSERVATION_MODIFIER", 299, 306], ["lung", "ANATOMY", 307, 311], ["disorders", "OBSERVATION", 312, 321]]], ["Our data from included countries also depicts similar observations in COVID-19 patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["Our data", "TEST", 0, 8]]], ["Importantly the deaths due to lung pathologies are significantly high compared to those hospitalized in Italy, Spain, France, and Sweden, contrary to the Netherlands.", [["lung", "ANATOMY", 30, 34], ["deaths", "DISEASE", 16, 22], ["lung pathologies", "DISEASE", 30, 46], ["lung", "ORGAN", 30, 34], ["lung pathologies", "PROBLEM", 30, 46], ["lung", "ANATOMY", 30, 34], ["pathologies", "OBSERVATION", 35, 46], ["significantly", "OBSERVATION_MODIFIER", 51, 64], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["Studies suggest that the SARS-CoV2 infection may efficiently serve as an additional factor to develop severe lung pathology (Li H. et al., 2020).", [["lung", "ANATOMY", 109, 113], ["SARS", "DISEASE", 25, 29], ["infection", "DISEASE", 35, 44], ["SARS-CoV2", "ORGANISM", 25, 34], ["lung", "ORGAN", 109, 113], ["Studies", "TEST", 0, 7], ["the SARS-CoV2 infection", "PROBLEM", 21, 44], ["severe lung pathology", "PROBLEM", 102, 123], ["SARS", "OBSERVATION", 25, 29], ["infection", "OBSERVATION", 35, 44], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["lung", "ANATOMY", 109, 113], ["pathology", "OBSERVATION", 114, 123]]], ["Hypoxia, pulmonary distress after SARS-CoV2 infection may hamper the anti-coagulating action of the endothelium by promoting thrombosis (Sardu et al., 2020; Tang et al., 2020).", [["pulmonary", "ANATOMY", 9, 18], ["endothelium", "ANATOMY", 100, 111], ["Hypoxia", "DISEASE", 0, 7], ["pulmonary distress", "DISEASE", 9, 27], ["SARS", "DISEASE", 34, 38], ["infection", "DISEASE", 44, 53], ["thrombosis", "DISEASE", 125, 135], ["pulmonary", "ORGAN", 9, 18], ["endothelium", "TISSUE", 100, 111], ["Hypoxia", "PROBLEM", 0, 7], ["pulmonary distress", "PROBLEM", 9, 27], ["SARS", "PROBLEM", 34, 38], ["CoV2 infection", "PROBLEM", 39, 53], ["promoting thrombosis", "PROBLEM", 115, 135], ["pulmonary", "ANATOMY", 9, 18], ["distress", "OBSERVATION", 19, 27], ["infection", "OBSERVATION", 44, 53], ["endothelium", "ANATOMY", 100, 111], ["thrombosis", "OBSERVATION", 125, 135]]], ["Treatment of such patients with Ruxolitinib, an antiviral, may result in pulmonary complications such as the rarely observed acute respiratory distress syndrome, and pulmonary hypertension exacerbations (Low et al., 2015; Kerget et al., 2017).DiscussionThe electron microscopic analysis reveals viral particles in the endothelial lining of glomerular capillary loops (Su et al., 2020).", [["pulmonary", "ANATOMY", 73, 82], ["respiratory", "ANATOMY", 131, 142], ["pulmonary", "ANATOMY", 166, 175], ["endothelial lining", "ANATOMY", 318, 336], ["glomerular capillary loops", "ANATOMY", 340, 366], ["Ruxolitinib", "CHEMICAL", 32, 43], ["acute respiratory distress syndrome", "DISEASE", 125, 160], ["pulmonary hypertension", "DISEASE", 166, 188], ["Ruxolitinib", "CHEMICAL", 32, 43], ["patients", "ORGANISM", 18, 26], ["Ruxolitinib", "SIMPLE_CHEMICAL", 32, 43], ["pulmonary", "ORGAN", 73, 82], ["pulmonary", "ORGAN", 166, 175], ["endothelial lining", "TISSUE", 318, 336], ["glomerular capillary loops", "TISSUE", 340, 366], ["patients", "SPECIES", 18, 26], ["Ruxolitinib", "TREATMENT", 32, 43], ["an antiviral", "TREATMENT", 45, 57], ["pulmonary complications", "PROBLEM", 73, 96], ["acute respiratory distress syndrome", "PROBLEM", 125, 160], ["pulmonary hypertension exacerbations", "PROBLEM", 166, 202], ["The electron microscopic analysis", "TEST", 253, 286], ["viral particles", "PROBLEM", 295, 310], ["pulmonary", "ANATOMY", 73, 82], ["complications", "OBSERVATION", 83, 96], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory distress", "OBSERVATION", 131, 151], ["syndrome", "OBSERVATION", 152, 160], ["pulmonary", "ANATOMY", 166, 175], ["hypertension", "OBSERVATION", 176, 188], ["viral particles", "OBSERVATION", 295, 310], ["endothelial", "ANATOMY_MODIFIER", 318, 329], ["lining", "ANATOMY_MODIFIER", 330, 336], ["glomerular", "ANATOMY_MODIFIER", 340, 350], ["capillary loops", "ANATOMY", 351, 366]]], ["These findings strengthen the association of COVID-19 with kidney disorders underlying endothelial function in it.", [["kidney", "ANATOMY", 59, 65], ["endothelial", "ANATOMY", 87, 98], ["kidney disorders", "DISEASE", 59, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["kidney", "ORGAN", 59, 65], ["endothelial", "TISSUE", 87, 98], ["COVID", "PROTEIN", 45, 50], ["COVID", "TEST", 45, 50], ["kidney disorders", "PROBLEM", 59, 75], ["kidney", "ANATOMY", 59, 65], ["disorders", "OBSERVATION", 66, 75], ["endothelial function", "OBSERVATION", 87, 107]]], ["A study showed that more than 20% of critically ill COVID-19 patients were diagnosed with acute kidney injury (Richardson et al., 2020).", [["kidney", "ANATOMY", 96, 102], ["critically ill", "DISEASE", 37, 51], ["acute kidney injury", "DISEASE", 90, 109], ["patients", "ORGANISM", 61, 69], ["kidney", "ORGAN", 96, 102], ["patients", "SPECIES", 61, 69], ["A study", "TEST", 0, 7], ["critically ill COVID", "PROBLEM", 37, 57], ["acute kidney injury", "PROBLEM", 90, 109], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["kidney", "ANATOMY", 96, 102], ["injury", "OBSERVATION", 103, 109]]], ["Our study clearly demonstrates a significant population of the deceased with kidney disorders compared to hospitalized patients for all the countries under consideration.", [["kidney", "ANATOMY", 77, 83], ["kidney disorders", "DISEASE", 77, 93], ["kidney", "ORGAN", 77, 83], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["Our study", "TEST", 0, 9], ["kidney disorders", "PROBLEM", 77, 93], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["population", "OBSERVATION", 45, 55], ["kidney", "ANATOMY", 77, 83], ["disorders", "OBSERVATION", 84, 93]]], ["Besides, COVID-19 patients with cytokine release syndrome may develop acute kidney injury as an outcome of elevated vascular permeability, intrarenal inflammation, volume depletion, and cardiomyopathy (Ronco and Reis, 2020).", [["kidney", "ANATOMY", 76, 82], ["vascular", "ANATOMY", 116, 124], ["intrarenal", "ANATOMY", 139, 149], ["acute kidney injury", "DISEASE", 70, 89], ["inflammation", "DISEASE", 150, 162], ["cardiomyopathy", "DISEASE", 186, 200], ["patients", "ORGANISM", 18, 26], ["kidney", "ORGAN", 76, 82], ["vascular", "MULTI-TISSUE_STRUCTURE", 116, 124], ["intrarenal", "MULTI-TISSUE_STRUCTURE", 139, 149], ["cytokine", "PROTEIN", 32, 40], ["patients", "SPECIES", 18, 26], ["cytokine release syndrome", "PROBLEM", 32, 57], ["acute kidney injury", "PROBLEM", 70, 89], ["elevated vascular permeability", "PROBLEM", 107, 137], ["intrarenal inflammation", "PROBLEM", 139, 162], ["volume depletion", "PROBLEM", 164, 180], ["cardiomyopathy", "PROBLEM", 186, 200], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["kidney", "ANATOMY", 76, 82], ["injury", "OBSERVATION", 83, 89], ["elevated", "OBSERVATION", 107, 115], ["vascular", "ANATOMY", 116, 124], ["permeability", "OBSERVATION", 125, 137], ["intrarenal", "ANATOMY", 139, 149], ["inflammation", "OBSERVATION", 150, 162], ["volume depletion", "OBSERVATION", 164, 180], ["cardiomyopathy", "OBSERVATION", 186, 200]]], ["The treatment for COVID-19 includes Remdesivir and Losartan which have possible renal side-effects (Grein et al., 2020).", [["renal", "ANATOMY", 80, 85], ["COVID-19", "CHEMICAL", 18, 26], ["Remdesivir", "CHEMICAL", 36, 46], ["Losartan", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 18, 26], ["Remdesivir", "CHEMICAL", 36, 46], ["Losartan", "CHEMICAL", 51, 59], ["COVID-19", "SIMPLE_CHEMICAL", 18, 26], ["Remdesivir", "SIMPLE_CHEMICAL", 36, 46], ["Losartan", "SIMPLE_CHEMICAL", 51, 59], ["renal", "ORGAN", 80, 85], ["The treatment", "TREATMENT", 0, 13], ["COVID", "TEST", 18, 23], ["Remdesivir", "TREATMENT", 36, 46], ["Losartan", "TREATMENT", 51, 59], ["renal side-effects", "PROBLEM", 80, 98], ["renal", "ANATOMY", 80, 85]]], ["Prior knowledge of an individual\u2019s medical history can facilitate better treatment to COVID-19 patients rather than adding up to the disease misery.DiscussionOther comorbidities like immunodeficient conditions and neurological diseases are reported for some countries namely France, the Netherlands, and Sweden.", [["neurological", "ANATOMY", 214, 226], ["immunodeficient conditions", "DISEASE", 183, 209], ["neurological diseases", "DISEASE", 214, 235], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["DiscussionOther comorbidities", "PROBLEM", 148, 177], ["immunodeficient conditions", "PROBLEM", 183, 209], ["neurological diseases", "PROBLEM", 214, 235]]], ["Patients with immunodeficiency include individuals with compromised immune systems like AIDS or undergoing any immunosuppressive therapy.", [["immunodeficiency", "DISEASE", 14, 30], ["AIDS", "DISEASE", 88, 92], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["immunodeficiency", "PROBLEM", 14, 30], ["individuals", "PROBLEM", 39, 50], ["compromised immune systems", "PROBLEM", 56, 82], ["AIDS", "PROBLEM", 88, 92], ["any immunosuppressive therapy", "TREATMENT", 107, 136], ["immunodeficiency", "OBSERVATION", 14, 30]]], ["Notably, the antiviral therapies given to AIDS patients may slightly benefit in COVID-19 recovery as well (H\u00e4rter et al., 2020).", [["AIDS", "DISEASE", 42, 46], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["the antiviral therapies", "TREATMENT", 9, 32]]], ["Further, since the immune system is suppressed, these patients are highly susceptible to opportunistic pathogens, including SARS-CoV2.", [["immune system", "ANATOMY", 19, 32], ["opportunistic pathogens", "DISEASE", 89, 112], ["SARS-CoV2", "DISEASE", 124, 133], ["patients", "ORGANISM", 54, 62], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 124, 133], ["patients", "SPECIES", 54, 62], ["opportunistic pathogens", "PROBLEM", 89, 112], ["SARS", "PROBLEM", 124, 128]]], ["Therefore, we obtained variations in death reports compared to hospitalized patients from different countries.", [["death", "DISEASE", 37, 42], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84]]], ["Briefly, severe COVID-19 patients report acute cerebrovascular disease, conscious disturbance, and muscle injury.", [["cerebrovascular", "ANATOMY", 47, 62], ["muscle", "ANATOMY", 99, 105], ["acute cerebrovascular disease", "DISEASE", 41, 70], ["conscious disturbance", "DISEASE", 72, 93], ["muscle injury", "DISEASE", 99, 112], ["patients", "ORGANISM", 25, 33], ["muscle", "ORGAN", 99, 105], ["patients", "SPECIES", 25, 33], ["severe COVID", "PROBLEM", 9, 21], ["acute cerebrovascular disease", "PROBLEM", 41, 70], ["conscious disturbance", "PROBLEM", 72, 93], ["muscle injury", "PROBLEM", 99, 112], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["cerebrovascular", "ANATOMY", 47, 62], ["disease", "OBSERVATION", 63, 70], ["muscle", "ANATOMY", 99, 105], ["injury", "OBSERVATION", 106, 112]]], ["Plausibly SARS-CoV2 may invade the cerebrovascular and nervous system using ACE2 receptors, or the patients with a priori abnormal neurological conditions might be prone to SARS-CoV2 (Liguori et al., 2020).", [["cerebrovascular", "ANATOMY", 35, 50], ["nervous system", "ANATOMY", 55, 69], ["neurological", "ANATOMY", 131, 143], ["SARS", "DISEASE", 10, 14], ["SARS", "DISEASE", 173, 177], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 10, 19], ["cerebrovascular", "ANATOMICAL_SYSTEM", 35, 50], ["nervous system", "ANATOMICAL_SYSTEM", 55, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["patients", "ORGANISM", 99, 107], ["ACE2 receptors", "PROTEIN", 76, 90], ["patients", "SPECIES", 99, 107], ["ACE2 receptors", "TREATMENT", 76, 90], ["a priori abnormal neurological conditions", "PROBLEM", 113, 154], ["cerebrovascular", "ANATOMY", 35, 50], ["nervous system", "ANATOMY", 55, 69]]], ["COVID-19 patients with neurological conditions may result in poor prognosis and might die due to unrevealed complications.", [["neurological", "ANATOMY", 23, 35], ["neurological conditions", "DISEASE", 23, 46], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["neurological conditions", "PROBLEM", 23, 46], ["complications", "PROBLEM", 108, 121]]], ["A case study by Mao et al. (2020) demonstrated that neural manifestations were significantly more common in severe infections compared with non-severe infections.", [["neural", "ANATOMY", 52, 58], ["infections", "DISEASE", 115, 125], ["infections", "DISEASE", 151, 161], ["A case study", "TEST", 0, 12], ["neural manifestations", "PROBLEM", 52, 73], ["severe infections", "PROBLEM", 108, 125], ["non-severe infections", "PROBLEM", 140, 161], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["infections", "OBSERVATION", 115, 125], ["non-severe", "OBSERVATION_MODIFIER", 140, 150], ["infections", "OBSERVATION", 151, 161]]], ["Losartan and Tocilizumab recommended for COVID-19 are previously reported to have adverse neurological effects.", [["neurological", "ANATOMY", 90, 102], ["Losartan", "CHEMICAL", 0, 8], ["Tocilizumab", "CHEMICAL", 13, 24], ["Losartan", "CHEMICAL", 0, 8], ["Tocilizumab", "CHEMICAL", 13, 24], ["Losartan", "SIMPLE_CHEMICAL", 0, 8], ["Tocilizumab", "SIMPLE_CHEMICAL", 13, 24], ["Losartan", "TREATMENT", 0, 8], ["Tocilizumab", "TREATMENT", 13, 24], ["COVID", "TREATMENT", 41, 46], ["adverse neurological effects", "PROBLEM", 82, 110]]], ["Thus a proper combination of medication may be adopted.DiscussionConclusively, COVID-19 associated comorbidities and deaths were ostensibly similar in some parts of the world.", [["deaths", "DISEASE", 117, 123], ["medication", "TREATMENT", 29, 39], ["associated comorbidities", "PROBLEM", 88, 112], ["deaths", "PROBLEM", 117, 123]]], ["How fast we are able to identify the virus-induced disorder in a person with certain comorbidity is equally important.", [["disorder", "DISEASE", 51, 59], ["person", "SPECIES", 65, 71], ["the virus-induced disorder", "PROBLEM", 33, 59], ["certain comorbidity", "PROBLEM", 77, 96]]], ["It will enable to render the person with a suitable treatment plan within a safer timeframe.", [["person", "SPECIES", 29, 35], ["a suitable treatment plan", "TREATMENT", 41, 66]]], ["In addition, the outcomes of COVID-19 may be independent of the comorbidities; we have efficiently corroborated available data based on hospitalized and deceased COVID-19 patients with associated comorbidities.", [["COVID-19", "CHEMICAL", 29, 37], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["COVID", "TEST", 29, 34], ["the comorbidities", "PROBLEM", 60, 77], ["associated comorbidities", "PROBLEM", 185, 209]]], ["For example, in terms of hospitalized cases, the patients in ICU are included or excluded is not specified in the report from Netherlands.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57]]], ["Information regarding comorbidity patients of several categories is not presented in the case of Spain.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Many of the other comorbidities like smoking, obesity, cancer, etc. couldn\u2019t be considered in the study due to lack of information in most reports.", [["cancer", "ANATOMY", 55, 61], ["smoking", "CHEMICAL", 37, 44], ["obesity", "DISEASE", 46, 53], ["cancer", "DISEASE", 55, 61], ["cancer", "CANCER", 55, 61], ["obesity", "PROBLEM", 46, 53], ["cancer", "PROBLEM", 55, 61], ["the study", "TEST", 94, 103], ["comorbidities", "OBSERVATION", 18, 31], ["obesity", "OBSERVATION", 46, 53], ["cancer", "OBSERVATION", 55, 61]]], ["Furthermore, the information about hospitalization average length was not available in the reports from where the data is collected because the data was regarding on-going cases and not with respect to any completed trials or reports.", [["the data", "TEST", 110, 118]]], ["Nonetheless, cardiovascular diseases and diabetes were the most prominent of all in Italy, France, and Spain.", [["cardiovascular", "ANATOMY", 13, 27], ["cardiovascular diseases", "DISEASE", 13, 36], ["diabetes", "DISEASE", 41, 49], ["cardiovascular", "ANATOMICAL_SYSTEM", 13, 27], ["cardiovascular diseases", "PROBLEM", 13, 36], ["diabetes", "PROBLEM", 41, 49], ["cardiovascular", "ANATOMY", 13, 27], ["diseases", "OBSERVATION", 28, 36], ["diabetes", "OBSERVATION", 41, 49], ["most prominent", "OBSERVATION_MODIFIER", 59, 73]]], ["However, the pattern of the deceased population due to COVID-19 associated comorbidities, including cardiovascular diseases, diabetes, and chronic lung ailments for the Netherlands, is contrary to other countries.", [["cardiovascular", "ANATOMY", 100, 114], ["lung", "ANATOMY", 147, 151], ["cardiovascular diseases", "DISEASE", 100, 123], ["diabetes", "DISEASE", 125, 133], ["chronic lung ailments", "DISEASE", 139, 160], ["lung", "ORGAN", 147, 151], ["the deceased population", "PROBLEM", 24, 47], ["COVID-19 associated comorbidities", "PROBLEM", 55, 88], ["cardiovascular diseases", "PROBLEM", 100, 123], ["diabetes", "PROBLEM", 125, 133], ["chronic lung ailments", "PROBLEM", 139, 160], ["cardiovascular", "ANATOMY", 100, 114], ["diseases", "OBSERVATION", 115, 123], ["diabetes", "OBSERVATION", 125, 133], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["lung", "ANATOMY", 147, 151], ["ailments", "OBSERVATION", 152, 160]]], ["The possible higher association of these diseases with COVID-19 might be due to altered physiological conditions of an individual or plausibly due to side effects of the drugs used in the country as a prescription to treat COVID-19.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID", "DISEASE", 223, 228], ["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "CHEMICAL", 223, 231], ["COVID-19", "GENE_OR_GENE_PRODUCT", 55, 63], ["these diseases", "PROBLEM", 35, 49], ["COVID", "TEST", 55, 60], ["altered physiological conditions", "PROBLEM", 80, 112], ["the drugs", "TREATMENT", 166, 175], ["COVID", "TEST", 223, 228], ["possible", "UNCERTAINTY", 4, 12], ["higher", "OBSERVATION_MODIFIER", 13, 19], ["diseases", "OBSERVATION", 41, 49]]], ["This clearly shows that prior knowledge of an individual\u2019s health is critical to avoid fatal repercussions of COVID-19 treatment.Data Availability StatementAll datasets presented in this study are included in the article/supplementary material.Author ContributionsHJ, SJ, OI, and BB were involved in the final development of the project and manuscript preparation.", [["COVID-19", "CHEMICAL", 110, 118], ["COVID-19", "CHEMICAL", 110, 118], ["COVID-19 treatment", "TREATMENT", 110, 128], ["this study", "TEST", 182, 192], ["OI", "PROBLEM", 272, 274], ["BB", "TREATMENT", 280, 282], ["manuscript preparation", "TREATMENT", 341, 363]]], ["SJ, OI, and BB wrote the manuscript draft.", [["OI", "DISEASE", 4, 6], ["OI", "PROBLEM", 4, 6], ["BB", "TREATMENT", 12, 14]]], ["SJ, OI, NV, BB, and HJ analyzed the data.", [["BB", "TREATMENT", 12, 14], ["HJ", "TREATMENT", 20, 22]]], ["BB, NV, OI, AD, SC, and DK extracted the data.", [["OI", "DISEASE", 8, 10], ["AD", "DISEASE", 12, 14], ["BB", "MULTI-TISSUE_STRUCTURE", 0, 2], ["OI", "PROBLEM", 8, 10], ["NV", "OBSERVATION", 4, 6]]]], "4dc555f5a859dbbc0990dd2c7192884c581cd709": [["150 inclusive of all trials on drugs and plasma, we did not limit our inclusion criteria to randomized trials.", [["plasma", "ANATOMY", 41, 47], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["drugs", "TREATMENT", 31, 36], ["plasma", "TREATMENT", 41, 47]]], ["151 Second, we included studies where drugs or plasma was the primary intervention.", [["plasma", "ANATOMY", 47, 53], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["studies", "TEST", 24, 31], ["drugs", "TREATMENT", 38, 43], ["plasma", "TREATMENT", 47, 53], ["the primary intervention", "TREATMENT", 58, 82]]], ["Since there was not 152 standardized information about the components of each intervention, two individuals (KM, HM)", [["each intervention", "TREATMENT", 73, 90]]]], "PMC7261439": [["Funding/SupportNo third-party funding was received for this study.CRediT authorship contribution statement", [["this study", "TEST", 55, 65]]]], "PMC7510733": [["To the Editor: I read with interest the recent synopsis by Park et al. (1) about a coronavirus disease outbreak in a call center, in which I was involved as a field epidemiologist.", [["coronavirus disease", "DISEASE", 83, 102], ["coronavirus", "ORGANISM", 83, 94], ["a coronavirus disease outbreak", "PROBLEM", 81, 111], ["coronavirus disease", "OBSERVATION", 83, 102]]]], "8cc7283a6585093d463a1e75ee2825a941beacaa": [["Dear Editor,The SARS-CoV-2 (COVID-19) pandemic has resulted in an unprecedented disruption of surgical services and training around the world.", [["SARS", "DISEASE", 16, 20], ["SARS-CoV", "SPECIES", 16, 24], ["The SARS", "TEST", 12, 20], ["pandemic", "PROBLEM", 38, 46], ["surgical services", "TREATMENT", 94, 111]]], ["1 However, faced with significant pressure and evolving challenges, many surgeons have united in an impressive, proactive response leading to the rapid reorganisation of services and significant innovation.", [["significant pressure", "PROBLEM", 22, 42], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["pressure", "OBSERVATION", 34, 42], ["significant", "OBSERVATION_MODIFIER", 183, 194], ["innovation", "OBSERVATION", 195, 205]]], ["2 Junior doctors embarking on surgical training in August face uncertainty, a markedly different training landscape, and justifiable concerns about their ongoing professional development.", [["surgical training", "TREATMENT", 30, 47]]], ["However, this article highlights the many excellent training opportunities that still exist that should adequately bridge the gap until a more recognisable model of training resumes.Dear Editor,Core surgical trainees starting in August, and those returning to their posts after redeployment, face new rota patterns and the ever-present concern of a 'second wave' causing further disruption to training.", [["a 'second wave'", "PROBLEM", 347, 362], ["further disruption", "PROBLEM", 371, 389]]], ["Undoubtedly, the current climate is putting significant pressure on a cohort that has already been under considerable strain in recent months.", [["significant pressure", "PROBLEM", 44, 64], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["pressure", "OBSERVATION_MODIFIER", 56, 64]]], ["In addition to changes in working practises, trainees have seen exams, conferences, courses and teaching programmes cancelled across the United Kingdom.Dear Editor,Furthermore, disruption to laboratories and clinical trials may limit progress for trainees looking to pursue an integrated academic pathway in the future.Dear Editor,However, although the surgical training landscape has changed, seemingly overnight, many excellent training opportunities exist that will be invaluable to any surgical trainee interested in a career in Plastic Surgery.", [["exams", "TEST", 64, 69]]], ["Also, as trainees reflect on their experiences of redeployment, many will have gained skills that will serve them well in their future careers.Dear Editor,The majority of non-urgent Plastic Surgery elective work has been suspended for the foreseeable future.", [["non-urgent Plastic Surgery", "TREATMENT", 171, 197]]], ["This includes microsurgical breast reconstruction, which will likely have a detrimental effect on competency attainment for senior trainees approaching completion of training.", [["breast", "ANATOMY", 28, 34], ["breast", "ORGAN", 28, 34], ["microsurgical breast reconstruction", "TREATMENT", 14, 49], ["breast", "ANATOMY", 28, 34], ["reconstruction", "OBSERVATION", 35, 49]]], ["However, there is still a substantial throughput of burns, trauma and skin cancer operating, all of which form the essential foundation of any successful registrar application.", [["skin cancer", "ANATOMY", 70, 81], ["burns", "DISEASE", 52, 57], ["trauma", "DISEASE", 59, 65], ["skin cancer", "DISEASE", 70, 81], ["skin cancer", "CANCER", 70, 81], ["burns", "PROBLEM", 52, 57], ["trauma", "PROBLEM", 59, 65], ["skin cancer", "PROBLEM", 70, 81], ["any successful registrar application", "TREATMENT", 139, 175], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["throughput", "OBSERVATION_MODIFIER", 38, 48], ["burns", "OBSERVATION", 52, 57], ["skin", "ANATOMY", 70, 74], ["cancer", "OBSERVATION", 75, 81]]], ["3 Much of the trauma and skin cancer work is performed under local anaesthetic, often away from main theatres and, as such, fewer restrictions apply.", [["skin cancer", "ANATOMY", 25, 36], ["trauma", "DISEASE", 14, 20], ["skin cancer", "DISEASE", 25, 36], ["skin cancer", "CANCER", 25, 36], ["the trauma", "PROBLEM", 10, 20], ["skin cancer", "PROBLEM", 25, 36], ["local anaesthetic", "TREATMENT", 61, 78], ["skin", "ANATOMY", 25, 29], ["cancer", "OBSERVATION", 30, 36]]], ["Furthermore, with a greater consultant presence in theatre, there are opportunities for trainees to obtain one-to-one training on index procedures that may not have been possible previously.Dear Editor,In addition to maximising exposure in theatre, there are a number of innovative ways to learn outside of the workplace.", [["index procedures", "TREATMENT", 130, 146], ["may not have been possible", "UNCERTAINTY", 152, 178]]], ["Low-cost tendon repair simulation on pigs' trotters, home microsurgery training platforms, and freely available simulation programmes (e.g. Touch Surgery\uf0d4) can all help to develop essential skills in Plastic Surgery.", [["tendon", "ANATOMY", 9, 15], ["tendon", "TISSUE", 9, 15], ["pigs", "ORGANISM", 37, 41], ["pigs", "SPECIES", 37, 41], ["Low-cost tendon repair", "TREATMENT", 0, 22], ["pigs' trotters", "TREATMENT", 37, 51], ["home microsurgery training platforms", "TREATMENT", 53, 89], ["cost tendon repair", "OBSERVATION", 4, 22], ["Plastic Surgery", "OBSERVATION", 200, 215]]], ["4 In addition, courses such as the Duke and Penn Flap courses, are being run virtually and free-ofcharge; an opportunity to learn from internationally-renowned trainers without the substantial cost of attending in person.", [["person", "SPECIES", 214, 220], ["Penn Flap courses", "TREATMENT", 44, 61]]], ["Many departments are moving their teaching online, with a huge expansion of reconstructive webinars released since lockdown began.", [["webinars", "CANCER", 91, 99], ["a huge expansion of reconstructive webinars", "TREATMENT", 56, 99]]], ["5 Although many of these are pitched to higher level trainees, there are also resources that are ideal for core surgical trainees aiming to get to grips with the specialty, including the excellent 'Plastic Surgery Covered' series from the Plastic Surgery Trainees Association (PLASTA).", [["core surgical trainees", "TREATMENT", 107, 129]]], ["Rapid reorganisation of surgical services has created many new pathways that are ideal for audit, quality improvement and research projects.", [["surgical services", "TREATMENT", 24, 41], ["surgical", "OBSERVATION", 24, 32]]], ["The trainee redeployed to the emergency department may gain increased independence in basic wound care and the assessment and management of hand injuries, bites and other minor trauma.", [["wound", "ANATOMY", 92, 97], ["hand", "ANATOMY", 140, 144], ["injuries", "DISEASE", 145, 153], ["trauma", "DISEASE", 177, 183], ["wound", "PATHOLOGICAL_FORMATION", 92, 97], ["hand", "ORGANISM_SUBDIVISION", 140, 144], ["basic wound care", "TREATMENT", 86, 102], ["the assessment", "TEST", 107, 121], ["management", "TREATMENT", 126, 136], ["hand injuries", "PROBLEM", 140, 153], ["other minor trauma", "PROBLEM", 165, 183], ["hand", "ANATOMY", 140, 144], ["injuries", "OBSERVATION", 145, 153]]], ["In addition, the non-technical skills required to adapt quickly to an unfamiliar environment, remain up-to-date in a rapidly changing clinical crisis, communicate effectively with a new team, and navigate fraught interactions with patients and their relatives will serve any future surgeon well.Dear Editor,Aside from surgical training, trainee morale is justifiably low at present.", [["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["surgical training", "TREATMENT", 318, 335], ["surgical", "OBSERVATION", 318, 326]]], ["Despite considerable challenges, COVID-19 has brought with it an inventive and flexible approach to training; we hope this will continue as attention returns to training safe and confident surgeons of the future.CONFLICTS OF INTERESTNone", [["an inventive and flexible approach to training", "TREATMENT", 62, 108]]]], "c03623f7e5a36dd98c52bc35af23151d8789b37a": [["AbstractThe data of COVID-19 disease in China and then in South Korea were collected daily from several different official websites.", [["COVID", "TEST", 20, 25], ["19 disease in China", "PROBLEM", 26, 45], ["disease", "OBSERVATION", 29, 36]]], ["The collected data included 33 death cases in Wuhan city of Hubei province during early outbreak as well as confirmed cases and death toll in some specific regions, which were chosen as representatives from the perspective of the coronavirus outbreak in China.", [["death", "DISEASE", 31, 36], ["death", "DISEASE", 128, 133], ["coronavirus", "DISEASE", 230, 241], ["coronavirus", "ORGANISM", 230, 241], ["coronavirus", "OBSERVATION", 230, 241]]], ["Data were copied and pasted onto Excel spreadsheets to perform data analysis.AbstractA new methodology, Patient Information Based Algorithm (PIBA) [1] , has been adapted to process the data and used to estimate the death rate of COVID-19 in real-time.", [["death", "DISEASE", 215, 220], ["COVID-19", "CHEMICAL", 229, 237], ["data analysis", "TEST", 63, 76], ["COVID", "TEST", 229, 234]]], ["Assumption is that the number of days from inpatients to death fall into a pattern of normal distribution and the scores in normal distribution can be obtained by observing 33 death cases and analysing the data [2] .", [["death", "DISEASE", 57, 62], ["death", "DISEASE", 176, 181], ["normal", "OBSERVATION", 86, 92]]], ["We selected 5 scores in normal distribution of these durations as lagging days, which will be used in the following estimation of death rate.", [["death", "DISEASE", 130, 135], ["death rate", "TEST", 130, 140], ["normal", "OBSERVATION", 24, 30], ["distribution", "OBSERVATION_MODIFIER", 31, 43]]], ["We calculated each death rate on accumulative confirmed cases with each lagging day from the current data and then weighted every death rate with its corresponding possibility to obtain the total death rate on each day.", [["death", "DISEASE", 19, 24], ["death", "DISEASE", 130, 135], ["death", "DISEASE", 196, 201]]], ["While the trendline of these death rate curves meet the curve of current ratio between accumulative death cases and confirmed cases at some points in the near future, we considered that these intersections are within the range of real death rates.AbstractSix tables were presented to illustrate the PIBA method using data from China and South Korea.", [["death", "DISEASE", 29, 34], ["death", "DISEASE", 100, 105], ["death", "DISEASE", 235, 240], ["these death rate curves", "PROBLEM", 23, 46]]], ["Table Subject Death rate estimation using normal distribution, of mean, standard deviations and formulas.Specific subject areaThe data estimation focuses on the early estimation of death rate of infectious diseases, in particular, the disease COVID-19 caused by 2019-nCoV.Data formatCollected data are formatted on Excel spreadsheets for analysing.Parameters for data collectionData include the total number of patients, total number of deaths, daily numbers of new patients, daily number of new deaths, from starting data of official report to the presented time, e.g., March 22, 2020.Description of data collectionData were collected through the cyberlinke of each official websites and copied and pasted the desired data onto Excel spreadsheets.Value of the Data\uf0b7 These data provide the scientific community with a new methodology to estimate the death rate and then predict the death cases during an epidemic. \uf0b7 Scientific researchers, CDC employees, government officers for disease control and management, and public population, will benefit from these data. \uf0b7 These data will be very useful for the studies with the purpose either of disease control management or of related sources preparation to combat against an outbreak. \uf0b7 Due to the limited amount of data samples collected in this article, some factors, such as the phases of an outbreak and the measurements issued by the department of disease control that might impact the death rate of an epidemic, could be taken into for further insights and development of experiments with a large amount of data.", [["death", "DISEASE", 181, 186], ["infectious diseases", "DISEASE", 195, 214], ["deaths", "DISEASE", 437, 443], ["deaths", "DISEASE", 496, 502], ["death", "DISEASE", 850, 855], ["death", "DISEASE", 882, 887], ["death", "DISEASE", 1438, 1443], ["patients", "ORGANISM", 411, 419], ["patients", "ORGANISM", 466, 474], ["patients", "SPECIES", 411, 419], ["patients", "SPECIES", 466, 474], ["Death rate estimation", "TEST", 14, 35], ["infectious diseases", "PROBLEM", 195, 214], ["the disease COVID", "PROBLEM", 231, 248], ["Collected data", "TEST", 283, 297], ["data collection", "TEST", 363, 378], ["data collectionData", "TEST", 601, 620], ["disease control", "TREATMENT", 979, 994], ["management", "TREATMENT", 999, 1009], ["these data", "TEST", 1052, 1062], ["the studies", "TEST", 1101, 1112], ["disease control management", "TREATMENT", 1140, 1166], ["an outbreak", "PROBLEM", 1219, 1230], ["data samples", "TEST", 1263, 1275], ["disease control", "TREATMENT", 1400, 1415], ["distribution", "OBSERVATION_MODIFIER", 49, 61], ["area", "OBSERVATION_MODIFIER", 122, 126], ["infectious", "OBSERVATION", 195, 205]]], ["CHD-Coronary heart diseaseData DescriptionThe data of 33 death cases in table 1 have been collected from the official website of the Health Commission of Hubei Province in China, which include the date that patients have onset of symptoms, the date that patients began to be taken into ICU and the date of decease.", [["heart", "ANATOMY", 13, 18], ["CHD", "DISEASE", 0, 3], ["death", "DISEASE", 57, 62], ["heart", "ORGAN", 13, 18], ["patients", "ORGANISM", 207, 215], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 207, 215], ["patients", "SPECIES", 254, 262], ["CHD", "PROBLEM", 0, 3], ["Coronary heart diseaseData Description", "PROBLEM", 4, 42], ["symptoms", "PROBLEM", 230, 238], ["Coronary heart", "ANATOMY", 4, 18], ["diseaseData", "OBSERVATION", 19, 30]]], ["With these data, the days both from symptoms appearance to death and from ICU intake to death can be calculated.", [["death", "DISEASE", 59, 64], ["death", "DISEASE", 88, 93], ["symptoms", "PROBLEM", 36, 44]]], ["Following normal distribution, the mean score \u03bc and standard deviation \u03c3 can be calculated either.", [["the mean score", "TEST", 31, 45], ["normal", "OBSERVATION", 10, 16], ["distribution", "OBSERVATION_MODIFIER", 17, 29]]], ["Thus the 5 selected scores (\u03bc, \u03bc \u00b1 \u03c3 and \u03bc \u00b1 2\u03c3) in normal distribution can be obtain as the basic elements for the following estimation and prediction of death rate, which are respectively 2, 8, 13, 19, 25 days.", [["death", "DISEASE", 155, 160], ["the 5 selected scores", "TEST", 5, 26], ["death rate", "TEST", 155, 165], ["normal", "OBSERVATION", 52, 58]]], ["The disease information in table 2 has been collected from the public media before we resume data analysing with the same method of death rate estimation and prediction in South Korea as in China [1] .", [["death", "DISEASE", 132, 137], ["disease", "OBSERVATION", 4, 11]]], ["We have collected accumulative confirmed cases and deaths and then new confirmed cases and new deaths in South Korea.3-A: Death rate analysis in South KoreaDeath rate 1 from the date Symptoms 2020-03-15 2020-03-14 2020-03-13 2020-03-12 2020-03-11 Each score we selected in normal distribution has a specific possibility when we take them into consideration of representatives in bell curve [1] .", [["deaths", "DISEASE", 51, 57], ["deaths", "DISEASE", 95, 101], ["2020-03-15 2020-03-14 2020-03-13 2020-03-12 2020-03-11", "CHEMICAL", 192, 246], ["Death rate analysis", "TEST", 122, 141], ["South KoreaDeath rate", "TEST", 145, 166], ["Symptoms", "PROBLEM", 183, 191], ["new", "OBSERVATION_MODIFIER", 91, 94]]], ["When we weighted each death rate on a day with their corresponding possibilities and then sum, the total death rate on each day can be obtained.3-A: Death rate analysis in South KoreaEach curve consisting of several death rate will have a trendline and thus a formula to describe this trend as well as the current ratio between accumulative death cases and confirmed cases on each day (Table 4 ).", [["death", "DISEASE", 22, 27], ["death", "DISEASE", 105, 110], ["death", "DISEASE", 216, 221], ["death", "DISEASE", 341, 346], ["the total death rate", "TEST", 95, 115], ["Death rate analysis", "TEST", 149, 168], ["South KoreaEach curve", "TREATMENT", 172, 193]]], ["2020-03-15 2020-03-14 2020-03-13 2020-03-12 2020-03-11 Current ratio between accumulative death cases and confirmed cases3-A: Death rate analysis in South KoreaThe current ratio between accumulative death cases and confirmed cases is calculated by dividing accumulative death cases with accumulative confirmed cases on each day.5-B:The intersect points of three trendlines intersect 1 intersect 2Max. valueDeath rate in South Korea 0.92% 1.06%1.06%The trendlines of death rate 1 and death rate 2 tend to intersect with the trendline of the current ratio finally, because the current ratio will be the real death rate at the end of epidemic.", [["2020-03-15 2020-03-14 2020-03-13 2020-03-12 2020-03-11", "CHEMICAL", 0, 54], ["death", "DISEASE", 90, 95], ["death", "DISEASE", 199, 204], ["death", "DISEASE", 270, 275], ["5-B", "CHEMICAL", 328, 331], ["death", "DISEASE", 466, 471], ["death", "DISEASE", 483, 488], ["death", "DISEASE", 606, 611], ["5-B", "CHEMICAL", 328, 331], ["5-B", "SIMPLE_CHEMICAL", 328, 331], ["Death rate analysis", "TEST", 126, 145], ["The current ratio", "TEST", 160, 177], ["valueDeath rate", "TEST", 401, 416], ["death rate", "TEST", 466, 476], ["death rate", "TEST", 483, 493], ["epidemic", "PROBLEM", 631, 639]]], ["We considered that the intersection value of three trendline (death rate1 and 2, current ratio) will drop in the range of real death rate.", [["death", "DISEASE", 62, 67], ["death", "DISEASE", 127, 132], ["the intersection value", "TEST", 19, 41], ["death rate1", "TEST", 62, 73]]], ["When we calculated the death rate separately with the corresponding formula of their trendlines, two intersections have been acquired (Table 5-B) .", [["death", "DISEASE", 23, 28]]], ["We pick the maximum value between them to predict new death cases in the following days (Table 6 ).Experimental Design, Materials, and MethodsTables are produced based on the Patient Information Based Algorithm (PIBA) [1] .", [["death", "DISEASE", 54, 59], ["Experimental Design, Materials", "TREATMENT", 99, 129]]], ["PIBA has been adapted when estimating the death rate of COVID-19 in Real-time with publicly posted data.", [["PIBA", "CHEMICAL", 0, 4], ["death", "DISEASE", 42, 47], ["PIBA", "SIMPLE_CHEMICAL", 0, 4], ["PIBA", "PROTEIN", 0, 4], ["the death rate", "TEST", 38, 52], ["COVID", "TEST", 56, 61]]], ["Following normal distribution, the different durations with different possibilities between symptom appearance and death have been derived from analysing 33 death cases in Wuhan city of Hubei province in China [2] .", [["death", "DISEASE", 115, 120], ["death", "DISEASE", 157, 162], ["symptom appearance", "PROBLEM", 92, 110], ["death", "PROBLEM", 115, 120], ["normal", "OBSERVATION", 10, 16], ["distribution", "OBSERVATION_MODIFIER", 17, 29]]], ["Based on these results, the total death rate in regions can be calculated specifically by putting in the different death rates with different durations together.", [["death", "DISEASE", 34, 39], ["death", "DISEASE", 115, 120], ["the total death rate", "PROBLEM", 24, 44]]], ["While the trendline of these death rate curves meet the curve of current ratio between accumulative death cases and confirmed cases at some points in the near future, we considered that these intersections are within the range of real death rates.", [["death", "DISEASE", 29, 34], ["death", "DISEASE", 100, 105], ["death", "DISEASE", 235, 240], ["these death rate curves", "PROBLEM", 23, 46]]], ["The data analysis was all following normal distribution, either in calculating the possibility of every selected score or in estimating the death rate.Experimental Design, Materials, and MethodsAfter collection of data of COVID patients from South Korea, the data was analysed with PIBA method as indicated above ( Table 2 ).", [["death", "DISEASE", 140, 145], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["The data analysis", "TEST", 0, 17], ["the data", "TEST", 255, 263], ["PIBA method", "TREATMENT", 282, 293]]], ["The death rate was first estimated ( Table 3 ).", [["death", "DISEASE", 4, 9], ["The death rate", "TEST", 0, 14]]], ["The death rate then was calculated (Table 4 ).", [["death", "DISEASE", 4, 9], ["The death rate", "TEST", 0, 14]]], ["Following estimations, the PIBA method then was used to predict the number of deaths in the following week (Table 5 ).", [["deaths", "DISEASE", 78, 84], ["the PIBA method", "TREATMENT", 23, 38]]], ["The predicated death numbers then were compared to the real death numbers (Table 6 ). considerably lower than expected.", [["death", "DISEASE", 15, 20], ["death", "DISEASE", 60, 65], ["lower", "OBSERVATION_MODIFIER", 99, 104]]], ["Prior expectation has been much higher, based on multiple infectious routes [3] [4] .", [["much higher", "OBSERVATION_MODIFIER", 27, 38]]], ["Using our formula, the results indicate that the current infectious rate is even lower than the rate based on the total numbers (see Fig. 1A ).", [["the current infectious rate", "TEST", 45, 72], ["infectious", "OBSERVATION", 57, 67]]], ["The infectious rate in Hubei province is currently around 4%, although previously the rate was as high as 39%.", [["The infectious rate", "PROBLEM", 0, 19], ["the rate", "TEST", 82, 90], ["infectious", "OBSERVATION_MODIFIER", 4, 14]]], ["On average, the infectious rate overall in China is about 4%, while in Hubei it is 10%.", [["the infectious rate", "TEST", 12, 31], ["average", "OBSERVATION_MODIFIER", 3, 10], ["infectious", "OBSERVATION_MODIFIER", 16, 26]]], ["Among the inpatients, the rate in serious medical condition ranges from 10% to 30% (see Fig. 1B ), while it averages at 18% in China, 19% in Hubei, and 13% in the rest of country (except Hubei).", [["the rate", "TEST", 22, 30]]], ["Based on the estimated death rate, on January 22, there should be a total of 150 to 300 inpatients (see Fig. 5C ).", [["death", "DISEASE", 23, 28], ["the estimated death rate", "TEST", 9, 33]]], ["Based on the rate of patients who are severely ill among all patients, on January 2, there should be 216 to 315 patients.Experimental Design, Materials, and MethodsBased on the effective infection rate and based on the assumption of one week or 14 days from close contact to the onset of symptoms, there might be 2,160 to 68,478 people who were infected around December 20, 2019.", [["infection", "DISEASE", 187, 196], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 112, 120], ["people", "ORGANISM", 329, 335], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 112, 120], ["people", "SPECIES", 329, 335], ["severely ill", "PROBLEM", 38, 50], ["MethodsBased", "TREATMENT", 157, 169], ["the effective infection rate", "PROBLEM", 173, 201], ["symptoms", "PROBLEM", 288, 296], ["infection", "OBSERVATION", 187, 196]]], ["If we believe the epidemic doubling time is approximately 6 days, the initial infection source may date back to as early as November or October 2019.", [["infection", "DISEASE", 78, 87], ["the initial infection source", "PROBLEM", 66, 94], ["infection", "OBSERVATION", 78, 87]]]]}